The effectiveness of a brief intervention for illicit drugs linked to the alcohol, smoking and substance involvement screening test (ASSIST) in primary health care settings: a technical report of phase iii findings of the WHO ASSIST randomized controlled trial. by Humeniuk, Rachel et al.
WHO ASSIST Phase III Technical Report  
 1 
 
 
The Effectiveness of a Brief Intervention 
for Illicit Drugs Linked to the Alcohol, 
Smoking and Substance Involvement 
Screening Test (ASSIST) in Primary Health 
Care Settings: 
 
A Technical Report of Phase III Findings of the 
WHO ASSIST Randomized Controlled Trial 
 
 
 
 
 
 
Prepared by Rachel Humeniuk, Victoria Dennington & Robert Ali 
on behalf of the WHO ASSIST Phase III Study Group 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Management of Substance Abuse 
Department of Mental Health and Substance Abuse 
WHO ASSIST Phase III Technical Report  
 2 
WHO Library Cataloguing-in-Publication Data 
 
  
Humeniuk, Rachel 
 
 The effectiveness of a brief intervention for illicit drugs linked to the alcohol, smoking 
and substance involvement screening test (ASSIST) in primary health care settings : 
a technical report of phase III findings of the WHO ASSIST randomized controlled 
trial [electronic resource] / prepared by Rachel Humeniuk, Victoria Dennington & 
Robert Ali on behalf of the WHO ASSIST Phase III Study Group 
 
1.Substance abuse detection - methods. 2.Clinical trials, Phase III. 3.Evaluation 
studies. 4.Primary health care - utilization. I.Dennington, Victoria. II.Ali, Robert. 
III.World Health Organization. ASSIST Phase III Study Group. 
 
ISBN 978 92 4 159651 0    (NLM classification: WM 270) 
 
© World Health Organization 2008 
All rights reserved. Publications of the World Health Organization can be obtained from WHO 
Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 
791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int). Requests for permission to 
reproduce or translate WHO publications – whether for sale or for noncommercial distribution – 
should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: 
permissions@who.int).  
The designations employed and the presentation of the material in this publication do not imply 
the expression of any opinion whatsoever on the part of the World Health Organization 
concerning the legal status of any country, territory, city or area or of its authorities, or concerning 
the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border 
lines for which there may not yet be full agreement. 
 
The mention of specific companies or of certain manufacturers’ products does not imply that they 
are endorsed or recommended by the World Health Organization in preference to others of a 
similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary 
products are distinguished by initial capital letters. 
 
All reasonable precautions have been taken by the World Health Organization to verify the 
information contained in this publication.  However, the published material is being distributed 
without warranty of any kind, either expressed or implied.  The responsibility for the interpretation 
and use of the material lies with the reader.  In no event shall the World Health Organization be 
liable for damages arising from its use.   
 
The named authors alone are responsible for the views expressed in this publication. 
 
 
 
 
WHO ASSIST Phase III Technical Report  
 3 
ACKNOWLEDGEMENTS 
 
 
Phase III of the WHO ASSIST project was coordinated by the Drug & Alcohol Services 
South Australia (DASSA) and implemented by the WHO ASSIST Phase III Working 
Group which included: 
 
- Robert Ali (Drug & Alcohol Services South Australia, Adelaide, Australia) 
- Thomas Babor (Department of Community Medicine and Health Care, University 
of Connecticut School of Medicine, Farmington, United States of America) 
- Maria Lucia O. Souza-Formigoni (Universidade Federal de Sao Paulo, Sao 
Paulo, Brazil) 
- Rachel Humeniuk (Drug & Alcohol Services South Australia, Adelaide, Australia) 
- Roseli Boerngen de Lacerda (Department of Pharmacology, Universidade 
Federal do Parana, Curitiba, Brazil) 
- Walter Ling (Integrated Substance Abuse Programs, Jane & Terry Semel 
Institute for Neuroscience, Department of Psychiatry and Biobehavioral 
Sciences, David Geffen School of Medicine, UCLA, United States of America) 
- Bonnie McRee (Department of Community Medicine and Health Care, University 
of Connecticut School of Medicine, Farmington, United States of America) 
- David Newcombe (Drug & Alcohol Services South Australia, Adelaide, Australia) 
- Hemraj Pal (National Drug Dependence Treatment Centre and Department of 
Psychiatry, All India Institute of Medical Sciences, India) 
- Vladimir Poznyak (Department of Mental Health and Substance Abuse, World 
Health Organization, Geneva, Switzerland) 
- Sara Simon (Integrated Substance Abuse Programs, Jane & Terry Semel 
Institute for Neuroscience, Department of Psychiatry and Biobehavioral 
Sciences, David Geffen School of Medicine, UCLA, United States of America) 
- Janice Vendetti (Department of Community Medicine and Health Care, 
University of Connecticut School of Medicine, Farmington, United States of 
America) 
 
Victoria Dennington of Drug & Alcohol Services South Australia, Adelaide, 
Australia also played a significant role in the preparation of this report and the 
qualitative analysis of participant feedback from all sites involved. 
 
 
WHO ASSIST Phase III Technical Report  
 4 
The preparation of this document was coordinated by Vladimir Poznyak from the WHO 
Department of Mental Health and Substance Abuse, and Rachel Humeniuk and Robert Ali from 
Clinical Services and Research Division, Drug and Alcohol Services South Australia, WHO 
Collaborating Centre for Research in the Treatment of Drug and Alcohol Problems, Australia.  
Partial financial support for participation of the WHO Collaborating Centre for Research in the 
Treatment of Drug and Alcohol Problems in the WHO ASSIST Phase III Study was provided by 
the Australian Commonwealth Department of Health and Ageing.  Funding for participation of 
the sites in the United States of America was provided by the US National Institute on Drug 
Abuse (Grant # R01 DA016592). 
 
The authors also would like to thank the staff of the primary health care clinics 
involved for their generous cooperation and assistance in recruiting participants for 
this study. 
 
WHO ASSIST Phase III Technical Report  
 5 
 
 
EXECUTIVE SUMMARY 
 
 
 
There is substantial evidence of the benefits of screening and brief intervention for 
alcohol problems in primary health care (PHC) settings, however, there is currently a 
paucity of empirical information concerning the effectiveness of brief interventions (a) 
for illicit drug use; (b) as linked to screening outcomes, and (c) when used in primary 
health care settings. 
 
The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) was 
developed under the auspices of the World Health Organisation (WHO) by an 
international group of specialist addiction researchers and clinicians in response to the 
overwhelming public health burden associated with problematic substance use 
worldwide.  The ASSIST was designed to screen for problem or risky use of tobacco, 
alcohol, cannabis, cocaine, amphetamine-type stimulants (ATS), sedatives, 
hallucinogens, inhalants, opioids and ‘other drugs’.  A risk score is obtained for each 
substance and falls into either a ‘low’, ‘moderate’ or ‘high’ risk category which 
determines the type of intervention (‘none’, ‘brief intervention’, ‘brief intervention plus 
referral’). 
 
The primary aim of the ASSIST Phase III Project was to conduct an international 
randomized controlled trial (RCT) evaluating the effectiveness of a Brief Intervention 
(BI) for illicit drugs (cannabis, cocaine, ATS & opioids) as linked to the Alcohol, 
Smoking and Substance Involvement Screening Test (ASSIST).  Participants were 
recruited from PHC settings in four countries (Australia, Brazil, India, the United States 
of America) and were randomly allocated to an intervention or waitlist control group at 
baseline and followed up three months later.  Both groups were administered the 
ASSIST and a demographic profile questionnaire at baseline.  Intervention participants 
received a brief intervention for the drug for which they scored the highest on the 
ASSIST (either cannabis, cocaine, ATS or opioids).  They also received self-help 
materials relating to that drug.  After being administered the ASSIST at the 3-month 
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follow-up, the brief intervention participants were administered a semi-structured 
interview (Brief Intervention Process Rating Form) which asked for their views on the 
information and feedback they had received at the last interview three months ago.  For 
ethical reasons, control participants were given a brief intervention at the follow-up 
stage (after they had been administered the ASSIST).   
 
The ASSIST-linked BI was designed to be very short and easily linked to the score from 
the ASSIST screening questionnaire via the use of the ASSIST Feedback Report Card 
which records the participants’ ASSIST scores and presents the risks associated with 
the participants’ current pattern of substance use.  Furthermore, the ASSIST-linked BI 
incorporated FRAMES (Feedback, Responsibility, Advice, Menu, Empathy, Self-
efficacy) and motivational interviewing techniques that have been found to reduce client 
resistance while still facilitating change, the main components of which were Feedback, 
Responsibility and Advice.  Each country developed their own culturally appropriate 
brief intervention around these principles. 
 
ASSIST Total Illicit Substance Involvement Scores (calculated by the addition of all 
responses to Questions 1-8 excluding alcohol and tobacco) and ASSIST Specific 
Substance Involvement Scores for each Substance (calculated by the addition of 
responses to Questions 2-7 within each substance class) were determined, and two-
way repeated measures ANOVA (General Linear Model or GLM) were utilized to assess 
the effectiveness of the Brief Intervention.  Comparisons of these ASSIST scores at 
baseline and follow-up for both groups of participants (Control and BI) were conducted, 
in which control participants served to control for the effects of time and determine if 
there was a significant interaction effect.  GLM statistics were calculated for the total 
pooled sample (all countries), and also for each country where relevant.  Comparisons 
between countries were made initially with GLM and significant findings were further 
investigated with Tukey’s HSD post-hoc comparisons. 
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An integral aspect of this Phase III study was to investigate how participants perceived 
the feedback and information they had received and whether they had modified their 
attitude and substance use as a result.  During the follow-up interview participants who 
received the BI at baseline were asked for feedback on the information and feedback 
they had received (using the Brief Intervention Process Rating Form), and these 
responses were analysed using qualitative research techniques.  
 
A total of 731 participants were recruited from a variety of PHC settings for the 
international study (Australia n = 171; Brazil n = 165; India n = 177; United States of 
America n = 218).  The United States site comprised participants combined from two 
different states; California (n=40) and Connecticut (n=178).  Participants were aged 
between 16 and 62 years and scored between 4 and 26 (moderate risk) for cannabis, 
stimulants (cocaine or ATS) or opioids.  A total of 372 participants were randomly 
allocated to the BI group (50.9%) and 359 (49.1%) were randomized to the wait list 
Control Group.  A total of 395 participants were in the cannabis group, 247 in the 
stimulants group (92 cocaine; 155 ATS) and 89 were in the opioids group.  A total of 
628 participants were followed up (86%) and the remainder were lost to follow-up.   
 
The inferential analysis of the pooled data (i.e. all countries’ data combined) 
demonstrated that follow-up scores were significantly lower than baseline scores for 
Total Illicit Substance Involvement, Cannabis Specific Substance Involvement, 
Stimulant Specific Substance Involvement and Opioid Specific Substance Involvement.  
This first analysis did not differentiate between Control and BI groups and indicates that 
there was an overall decrease in substance use and risk over time.  However, when 
group type was taken into consideration, (i.e. Control or BI) participants receiving the 
brief intervention had significantly reduced scores for all measures (excluding Opioid 
Specific Substance Involvement) compared with Control participants.  These findings 
indicate that the brief intervention was effective compared with no intervention in 
getting participants to reduce their substance use and risk, as determined by the 
ASSIST questionnaire.  However, it also indicates that even when a brief intervention 
was not received (as in the case of Control participants at baseline) a reduction in 
ASSIST scores also was observed, albeit not to the same degree as the BI participants.   
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While a significant interaction effect was not observed for the Opioid Specific 
Substance Involvement Score with the pooled data, there certainly was a tendency for 
participants receiving the opioid-targeted BI to have lower scores at follow-up compared 
with the Control participants.  However, when Indian participants - who comprised the 
majority of opioid users - were considered on their own, there was a significant 
interaction effect (p<0.05).   
 
With the exception of the United States site, all countries demonstrated that the BI 
participants had significantly lower Total Illicit Substance Involvement scores at follow-
up compared with the Control subjects.  A similar pattern, including the lack of a brief 
intervention effect, also was observed for Cannabis and Stimulant Specific Substance 
Involvement Scores in participants recruited in the USA.  Conversely, Indian and 
Brazilian sites demonstrated a very strong brief intervention effect for Cannabis 
Specific Substance Involvement Scores (p<0.005), as did Australia (p<0.005) and Brazil 
(p<0.01) for Stimulant Specific Substance Involvement Scores. 
 
The reasons underlying the contrast between the Australian, Brazilian and Indian sites 
and the United States site with regards to a brief intervention effect was not completely 
clear.  However, there were some protocol and participant differences between the USA 
and other sites which may have contributed to the lack of a brief intervention effect.   
 
Results from this study also demonstrated that the reduction in illicit drug use due to 
the implementation of the ASSIST and linked BI did not appear to have resulted in 
increased use of other substances including tobacco, alcohol, inhalants, sedatives or 
hallucinogens.   
 
The ASSIST Brief Intervention Process Rating form was administered at the follow-up 
interview to a total of 372 participants (Australia n = 86; Brazil n = 94; India n = 89; 
USA n = 103) to determine how behaviour change occurred from an individual 
perspective.  Over eighty per cent (82.8%) of all participants who received the brief 
intervention at baseline reported attempting to cut down on their substance use as a 
result of the feedback and information they had received.  Of the participants who did 
manage to reduce their substance use (n=224, 60.2%) the average time participants 
maintained this reduction was 11.2 weeks.   
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Three main themes were identified overall regarding the feedback received (‘To help’, 
‘To inform’, ‘To raise awareness’) and were representative of the kinds of positive 
feedback received from participants about the ASSIST-linked BI process and its ability 
to raise awareness about levels of substance use and subsequent potential health 
effects of continued use.  Participants identified four main themes when considering the 
influence of the brief intervention on their health behaviour.  The themes ‘Cutting down’, 
‘Stopping use’, ‘Thinking about it’ and ‘Feeling better’ were identified from the analysis 
of comments from the 260 participants who stated the ASSIST-linked BI had influenced 
their health behaviour.  Conversely, participants who reported that the feedback and 
information they had received as part of the ASSIST-linked BI had no influence on their 
health behaviour  identified four themes, ‘Heard it all before’, ‘Choice’, ‘It’s not an issue’ 
and ‘I can’t give up’. 
 
Participants also were invited to comment on which aspects of the information and 
feedback most influenced their health behaviour around their substance use.  There 
were two dominant themes identified in the analysis ‘Obligations and responsibilities’ 
and ‘Identifying and defining the problem’.  The second theme: ‘Identifying and defining 
the problem’ centred on comments relating to three aspects of the information and 
feedback identified by participants as being most influential: 1) the score, 2) the 
interview and 3) 'hearing myself speak'.   
 
The success of incorporating motivational interviewing techniques into the ASSIST-
linked BI is evident in the comments outlined above, which illustrate some of the ways 
in which participants valued the opportunity to receive a personalized score regarding 
their risk and to hear themselves talk about the effects of their substance use more 
fully.  These comments also indicate that the opportunity to generate such ‘change-talk’ 
played an integral role in positively influencing their health behaviour. 
 
The findings from the qualitative analysis above are commensurate with the inferential 
analysis of the effectiveness of the brief intervention.  Participants’ comments pointed 
to the successful and appropriate incorporation of ASSIST scores within a motivational 
interviewing context.  The personal feedback given to participants through their ASSIST 
scores provided a non-confrontational way of drawing attention to the less positive 
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aspects (risks) of continued substance use in ways that elicited participants' own 
reasons for, and advantages of change.   
 
Overall it appears that the ASSIST-linked brief intervention was effective in getting 
participants to reduce their substance use and risk as measured by their ASSIST score 
and these findings were commensurate with participant feedback which was gathered at 
the 3-month follow-up interview. 
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1. INTRODUCTION 
 
There is a significant public health burden associated with substance use worldwide. 
Tobacco, alcohol and illicit drugs (heroin and cocaine) account for 8.8%, 3.2% and 
0.4% of all deaths respectively, and 4.1%, 4.0% and 0.8% of Disability Adjusted Life 
Years respectively.  Indeed, according to the 2002 World Health Report substance use 
is among the top 20 risk factors for death worldwide (World Health Organization, 2002).  
There is also evidence that the burden on the public health care system from risky, 
albeit non-dependent use, may be greater than the burden due to dependent use 
(Institute of Medicine, 1990; Skinner, 1987).  
 
There is substantial evidence of the benefits of screening and brief intervention for 
alcohol problems in primary health care (PHC) settings, particularly when the brief 
intervention is linked to the results of screening tests such as the Alcohol Use 
Disorders Identification Test (AUDIT) ((Babor et al., 2007; Bien et al., 1993; Cordoba et 
al., 1998; Heather, 1996; Maisto et al., 2001; Miller & Rollnick, 2002; Senft et al., 1997; 
WHO Brief Intervention Study Group, 1996).  The WHO Brief Intervention Study Group 
found that five minutes of simple advice, linked to the results of the AUDIT were as 
effective as 20 minutes of counselling (1996).  Moreover, brief interventions have been 
shown to be a cost effective way of reducing alcohol consumption and associated 
problems (Fleming et al., 2000; Wutzke et al., 2001). 
 
Screening and brief intervention for substance use other than alcohol might be effective 
in primary care settings if culturally appropriate procedures could be developed.  
However, compared with the number of studies for alcohol or tobacco, there is currently 
a paucity of empirical information concerning the effectiveness of brief interventions (a) 
for illicit drug use; (b) as linked to screening outcomes, and (c) when used in primary 
care settings ((Babor et al., 2007; Dunn et al., 2001).  Part of the reason for the scarcity 
of research may be a result of not having access to adequate screening instruments for 
substances other than alcohol or tobacco. 
 
There is evidence suggesting that brief interventions may work for non-alcohol, non-
tobacco drugs such as cannabis (Copeland et al., 2001; Lang et al., 2000; Stephens et 
al., 2000), benzodiazepines (Bashir et al., 1994), opioids (Saunders et al., 1995) and 
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cocaine (Stotts et al., 2001).  For example, patients with chronic benzodiazepine 
problems received brief advice lasting a few minutes and a self-help book, as part of a 
routine visit to a general practitioner.  The brief advice group significantly reduced their 
benzodiazepine use and showed improved general health both 3 and 6 months after the 
advice was given (Bashir et al., 1994).  In another study, regular amphetamine users – 
including dependent users, were recruited from a variety of health settings and 
assessed using a variety of procedures.  Participants were found to reduce their 
amphetamine use following a brief intervention which comprised two-four sessions of 
Cognitive Behavioural Therapy and a self-help book (Baker et al., 2001).  A randomized 
controlled trial conducted by Bernstein et al. (2004)  used a variety of drug and alcohol 
screening tests to assess clients recruited from walk-in primary health care clinics.  
Clients randomized to the brief intervention group were more likely to reduce their 
cocaine and heroin use than those not receiving the brief intervention.  In this US study, 
the brief intervention conducted by peer educators lasted an average of 20 minutes 
(range 10-45 min.) with an adjunct ten minute ‘booster’ intervention via telephone ten 
days later.  Finally, a pilot study amongst adolescents recruited from primary care 
settings showed that a 15-20 minute intervention linked to a brief self-report screening 
questionnaire resulted in attitudinal changes towards substance use and decisions to 
cut down (Stern et al., 2007).  This same study (Project CHAT) found that brief 
interventions based on motivational interviewing techniques were a viable approach for 
working with adolescents in primary care settings. 
 
While the above-mentioned studies demonstrate that brief interventions for drugs can 
be effective, it is worth noting that for the majority of the studies the brief intervention 
session lasted between 30 and 90 minutes and that the interventions were not 
necessarily linked to screening outcomes within primary care settings.  
 
In fact, until recently, a culturally-neutral screening questionnaire for all substances, 
including illicit drugs, has not been available for use in primary care settings. 
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1.1 The Alcohol Smoking and Substance Involvement Screening Test (ASSIST)  
The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) was 
developed under the auspices of the World Health Organisation (WHO) by an 
international group of specialist addiction researchers and clinicians in response to the 
overwhelming public health burden associated with problematic substance use 
worldwide.  The ASSIST was designed to screen for problem or risky use of tobacco, 
alcohol, cannabis, cocaine, amphetamine-type stimulants (ATS), sedatives, 
hallucinogens, inhalants, opioids and ‘other drugs’.  It is worth noting that methylene 
dioxymethamphetamine (MDMA), also commonly referred to as ecstasy, was included 
in the amphetamine-type stimulants category. 
 
The ASSIST has undergone significant testing (see below) to ensure that it is feasible, 
reliable, valid, flexible, comprehensive and cross-culturally relevant.  Phase I of the 
ASSIST project investigated test-retest reliability at the item level and scale level, and 
included qualitative data collection on feasibility and acceptability.  Two-hundred and 
thirty-six sets of test-retest interviews were completed by ten international sites in nine 
different countries.  Data were examined according to question stem, substance class 
and data collection setting in order to provide recommendations for improving the 
instrument.  Published results indicate that the ASSIST proved to be a reliable and 
feasible screening tool (WHO ASSIST Working Group, 2002).  
 
Phase II of the ASSIST project investigated the validity of the ASSIST for use in 
primary health care settings.  The validity study conducted with 1,047 subjects from 
seven different countries, demonstrated that the ASSIST had good concurrent, 
construct, predictive and discriminative validity.  A brief intervention linked to ASSIST 
scores also was piloted as part of Phase II and demonstrated that a brief intervention 
for alcohol was an effective way of significantly reducing alcohol ASSIST scores when 
compared with primary health care subjects who did not receive an intervention 
(Humeniuk et al., (In press); Humeniuk, 2006; Newcombe et al., 2005).  Similarly, the 
brief intervention was also shown to be effective for drugs other than alcohol (cannabis, 
opioids & cocaine) and ASSIST scores for these substances were significantly reduced 
by 23% from baseline to follow-up three months later. 
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The ASSIST V3.0 questionnaire (see APPENDIX 1) commences with a general 
screening question that asks about lifetime use of any psychoactive substance; if the 
respondent reports no use, the interview can be terminated.  If the respondent admits 
to lifetime use of one or more substances, the remaining questions need only to be 
asked with regard to those substances used.  Question 2 asks about frequency of use 
in the past three months.  If none of the substances have been used in the past three 
months, the interviewer can skip to the last three questions, which enquire about 
lifetime problems of those substances used.  Question 3 is a measure of psychological 
dependence and asks about frequency of strong compulsion to use substances in past 
three months.  Question 4 is a measure of harmful substance use, and asks how 
frequently the respondents’ drug use had led to health, social, legal or financial 
problems.  Question 5 asks whether respondents have failed to meet role obligations 
because of their use of substances (except tobacco).  Questions 6 to 8 ask about 
lifetime and recent problems, including whether friends or relatives have expressed 
concern, prior attempts at controlling drug use and prior injection of drugs during the 
past three months and in their lifetime. 
 
1.2 Phase III of the WHO ASSIST project 
The international WHO ASSIST Phase III project is based on the model used by the 
WHO to advance alcohol screening and brief intervention through the development of 
the Alcohol Use Disorders Identification Test (AUDIT) (Babor et al., 1989; Babor & 
Higgins-Biddle, 2001; Babor et al., 2001; WHO Brief Intervention Study Group, 1996).  
The primary aim of the Phase III Project was to conduct a cross-cultural randomized 
controlled trial (RCT) evaluating the effectiveness of a Brief Intervention (BI) for illicit 
drugs (cannabis, cocaine, ATS & opioids) as linked to the Alcohol, Smoking and 
Substance Involvement Screening Test (ASSIST).  It is worth noting that participants 
recruited to this study scored within the moderate risk range of the ASSIST only (i.e. 
between 4 and 26) and were not high risk, dependent users.  Participants in this group 
were at moderate risk of health and other problems because of their drug use and may 
have been currently experiencing problems or at risk of developing problems in the 
future including the risk of dependence.  
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1.3 The ASSIST-linked Brief Intervention 
It was intended that this study be as ‘real world’ as possible and hence it was expected 
that only a very brief intervention would be feasible in most primary care settings.  This 
was due to time constraints and a general reluctance by health care workers to deal 
with substance users.  Consequently, the length of the brief intervention was expected 
to vary from country to country depending on the time available to the clinician and their 
cultural style, but was intended to be between 5 and 15 minutes in duration.  
 
The aim of the ASSIST-linked Brief Intervention was to move participants through the 
stages of change using the technique of FRAMES and Motivational Interviewing (Bien 
et al., 1993; Miller & Rollnick, 2002).  The stages of change model proposes that 
individuals pass through recognised stages of change as they modify their own 
behaviour (Prochaska & DiClemente, 1982).  Each stage of the cycle of change reflects 
both a period of time and a set of tasks or processes of change required for movement 
to the next stage.  The specific stages of change include Pre-contemplation (not 
thinking about changing), Contemplation (thinking about change, weighing up the pros 
and cons and information/resource gathering) and Action (actually cutting down or 
stopping).  While stage of change was not formally measured in this study, the outcome 
measure of ASSIST score change and associated participant feedback was used as a 
marker of change. 
 
While it is clear that brief interventions are effective, particularly for alcohol, it appears 
that implementation and uptake within health settings may be hindered by a variety of 
barriers (Roche & Freeman, 2004).  The three main reasons perceived by clinical staff 
as barriers to taking up screening of alcohol screening and BI within PHC settings were: 
(1) a lack of time, (2) concern that patients will be defensive and, (3) a lack of staff 
knowledge and skills to conduct the screening and intervention (Barry et al., 2004).  
 
To combat the identified limitations, the ASSIST-linked BI was designed to be very 
short and easily linked to the score from the ASSIST screening questionnaire via the 
use of the ASSIST Feedback Report Card (See APPENDIX 2), which records the 
participants’ ASSIST scores and presents the risks associated with the participants’ 
current pattern of substance use.  Furthermore, the ASSIST-linked BI incorporated 
motivational interviewing techniques that have been found to reduce client resistance 
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while still facilitating change, the main components of which were Feedback and 
Advice.  Each country developed their own culturally appropriate brief intervention 
based around these principles (see, for an Australian example, Humeniuk et al., 2007).  
The brief intervention was further bolstered by a take-home guide called Self-help 
strategies for cutting down or stopping substance use: A guide (Humeniuk et al., 2003) 
which was a generic self-help booklet designed to take participants through the process 
of weighing up the risks associated with their substance use and providing simple 
strategies for change.  Booklets were translated into the local language where relevant.  
Each country also provided participants with specific drug information booklets 
developed for that country.   
 
1.4 Aims 
The primary aim of the Phase III WHO study was to undertake an international multi-
site collaborative project to evaluate the effectiveness of a Brief Intervention for illicit 
drugs (cannabis, cocaine, ATS & opioids) as linked to the ASSIST, in a variety of 
primary health care settings and in a number of different cultural contexts.  A secondary 
aim involved the development of client and clinician resources incorporating: 
instructions for administering the ASSIST and Brief Intervention; self-help materials on 
specific drugs and generic self-help strategies to reduce drug use; information on 
injecting risk, and a feedback report card on current drug use. 
 
While standard statistical techniques were used to determine if the BI was successful in 
reducing ASSIST scores, drug use and risk, these same techniques were less able to 
determine how the ASSIST-linked BI actually worked, which also was of interest in this 
study, and an area that is infrequently investigated by RCTs.  Nock (2007) proposed 
that “showing that a treatment causes change does not in itself illuminate how this 
change occurred” and identified three goals that should be shared by clinical 
researchers: “(1) to develop methods that decrease pathology and return individuals to 
healthy, adaptive functioning, (2) to elucidate the processes through which these 
methods have their effects, and (3) to identify the conditions that influence the efficacy 
of these methods” (p. 4S). 
 
Analysis of client talk has been shown to be an indicator of successful reduction or 
cessation of alcohol use and there is evidence that ‘client commitment language’ 
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occurring during motivational interviewing can predict drug use outcomes and “client 
language within treatment sessions is a promising mechanism for MI” (Amrhein et al., 
2003, p. 40S #184).  Accordingly participants who received the BI at baseline were 
asked for feedback on the information and feedback they had received at that time, and 
these responses were analysed using qualitative research techniques as described in 
the Methodology (2.8.2 Thematic Analysis on Participant Feedback at follow-up). 
 
Overall, the Phase III international study intended to provide answers to the following 
research questions: 
 
1. Does the ASSIST BI significantly reduce Total Illicit Substance Involvement
1
? 
 
2. Does the ASSIST BI reduce the Specific Substance Involvement Score
1
 
(cannabis, stimulants [cocaine and ATS], opioids) for which subjects received a 
Brief Intervention, and does the ASSIST-linked BI perform better for some illicit 
substances than others? 
 
3. Does reducing illicit substance use as a result of receiving a BI result in 
substitution with other substances? 
 
4. Do people who score higher within the moderate risk range (i.e., above 15) 
respond any differently to a specific brief intervention than people in the lower 
range (i.e., between 4 and 15)? 
 
5. Are there any differences between countries with regards to the above findings? 
 
6. Are the testimonies (feedback) of participants who received the brief intervention 
commensurate with the results of the quantitative analysis (Q1 – 3 above) and 
how did the ASSIST-linked BI create a change in drug use? 
 
                                                          
1
 See Section 2.7 on page 28 for a description of these scores 
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2. METHODOLOGY 
 
2.1 Countries Involved 
The project was conducted at Clinical Research Units (CRU’s) in four countries 
selected to represent the broad range of cultures, political and economic systems in 
which substance-related problems are prevalent, and to enhance the cross-national 
generalizability of the findings.  The sites were; 1) Australia: Drug and Alcohol Services 
South Australia (also the Coordinating Centre); 2) Brazil: Departamento de 
Psicobiologia, Universidade Federal de Sao Paulo, Sao Paulo - and - Departamento de 
Farmacologia, Universidade Federal do Parana Curitiba, Paraná; 3) India: National 
Drug Dependence Treatment Centre and Department of Psychiatry, All India Institute of 
Medical Sciences, New Delhi; 4) USA: UCLA Integrated Substance Abuse Programs & 
Friends Research Institute, Los Angeles – and – Department of Community Medicine 
and Health Care, University of Connecticut, School of Medicine, Connecticut. 
 
2.2 Overview 
The study employed a randomized controlled design in which eligible participants were 
randomly allocated to an intervention or waitlist control group at baseline and followed 
up three months later.  Both groups were administered the ASSIST and a demographic 
profile questionnaire at baseline.  Intervention participants received a brief intervention 
for the drug for which they scored the highest on the ASSIST (either; cannabis, 
cocaine, ATS or opioids).  They also received self-help materials relating to that drug.  
If participants scored within the moderate risk range for two or more of the target drugs, 
they were asked which substance was of the most concern to them, and the Brief 
Intervention was aimed at this substance.  Details about the Brief Intervention were 
recorded on a BI checklist (APPENDIX 8.3, “WHO ASSIST Brief Intervention Record”). 
Both groups were re-interviewed three months later with the ASSIST.  After being 
administered the ASSIST, the brief intervention participants were administered a semi-
structured interview which asked for their views on the information and feedback they 
had received at the last interview three months ago (APPENDIX 8.4, “WHO ASSIST 
Brief Intervention Process Rating Form – Follow up”).  For ethical reasons, control 
participants were placed on a waitlist for treatment, and were given a brief intervention 
at the follow-up stage (after they had been administered the ASSIST).  Details of the 
follow-up intervention were recorded on a “WHO ASSIST Brief Intervention Record” but 
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are not included in the results of this study.  With the exception of the Brazilian sites, 
participants were compensated for their time in the study and for travel relating to 
returning to the clinic for the second interview three months later. 
 
2.3 Settings 
The Primary Health Care (PHC) settings from which participants were recruited, and the 
periods over which recruitment took place, varied from country to country as outlined 
below. 
 
2.3.1 Australia 
Within Australia the Phase III study was conducted at a free, walk-in sexually 
transmitted disease service (Clinic 275) in metropolitan Adelaide, South Australia.  This 
clinic is linked to the Royal Adelaide Hospital and is the primary clinic for sexual health 
in South Australia.  Participants were recruited over two periods: September – October 
2003 and April 2004 – May 2005. 
 
2.3.2 Brazil 
2.3.2.1 Sao Paulo 
In São Paulo city, Phase III was conducted at four primary general health care units 
and two health centers which specialized in assessment and treatment of STDs.  In 
Diadema city 17 primary general health care units were used to recruit participants.  
Participants were recruited between July 2004 and November 2006. 
 
2.3.2.2 Curitiba 
Within Curitiba, Parana Phase III was conducted at nine free, primary general health 
care settings in metropolitan Curitiba, and at one free, walk-in primary general health 
care outpatient setting linked to a general hospital in Palmas city.  Both cities are 
located in South Brazil.  Participants were recruited over the period between August 
2004 and May 2006. 
 
2.3.3 India 
National Drug Dependence Treatment Centre and the Department of Psychiatry at All 
India Institute of Medical Sciences, New Delhi, India was involved in recruitment of the 
sample.  The sample was recruited from the community at Trilokpuri and border area of 
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Delhi with Ghaziabad called Shadipur and assessed at the Community Drug Treatment 
Centre in Trilokpuri.  The former was primarily used to recruit cannabis users whereas 
the latter, a community of transporters contributed to a mixed though predominantly 
opioid using sample.  The recruitment of study sample started in March 2004 and data 
collection finished in March 2005.  
 
2.3.4 United States of America 
2.3.4.1 California  
Within California the Phase III study was conducted both at a neighborhood clinic 
connected with UCLA, and at a walk-in health clinic associated with a drug treatment 
programme.  Participants were recruited between September and December 2005 and 
August and September 2006. 
 
2.3.4.2 Connecticut 
In the United States of America (Connecticut site), participants were recruited from a 
number of general medicine and dental clinics within the Hartford area.  The largest 
number of participants were recruited from the Advanced Education in General 
Dentistry Clinic at the University of Connecticut Health Center (UCHC).  This dental 
clinic serves as the primary dental provider for low-income and emergency dental 
patients in the state. The clinic houses 25 dental residents, and six dental assistants.  
On average, 40 of the 100 patients seen per day are emergency cases.  Participants 
were also recruited from the adult medicine and dental clinics at Community Health 
Services (CHS); a full-service Federally Qualified Health Center in Hartford. A small 
number of participants were recruited from the Internal Medicine Residency Clinic at 
UCHC, and less than one-third of the participants were referrals to the study.  
Participants were recruited from January 2005 through December 2006.  
 
2.4 Participants 
Participants were aged between 16 and 62 years and were clinic attendees.  
Participants who scored in the low risk range between 0 and 3 for cannabis, cocaine, 
ATS and opioids, and between 0 and 31 for tobacco, and between 0 and 26 for alcohol, 
hallucinogens, sedatives, inhalants or other drugs, were excluded from enrolment into 
the study, but received information on drugs if relevant. 
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Participants who scored between 4 and 26 (moderate risk) for cannabis, cocaine, ATS 
or opioids were enrolled in the study and randomized to either the Control or 
Intervention group.  
 
Participants who scored in the high risk category (27 or higher for any of the 
substances), or who had frequently injected drugs in the last three months (more than 4 
times per month on average) were excluded from enrolment into the study and were 
referred to specialist treatment services within that country. 
 
The following were the primary inclusion/exclusion criteria for recruitment to the study. 
Participants in the study were: 
 
1. between the ages of 16 and 62 years; 
2. a member of the main ethnic group(s) in the population; 
3. able to communicate in the main language of the country; 
4. willing to participate in a 3 month follow-up where they return to the treatment 
agency for interview; 
5. able to be followed up three months later and give contact details of at least 2-
3 other people; 
6. of fixed address and able to provide contact details of their home; 
7. not pending incarceration within the next three months; 
8. not severely cognitively impaired or have severe behaviour; 
10. not tended to violent or aggressive behaviour; 
11. physically well enough to participate in a 30 minute interview and intervention 
session; 
12. not intoxicated or going through withdrawal from alcohol or other drugs; 
13. not currently in drug (excluding nicotine) or alcohol treatment (within the last 
month), 
14. not incarcerated or in an environment where they were not able to come and 
go as they please in the last three months. 
 
2.5 Procedure 
Procedures varied slightly from country to country.  In Australia, India and the USA 
clinical research interviewers were trained by the Study Coordinator at each site to 
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administer the test battery, ASSIST and Brief Intervention.  For the purposes of this 
study, clinical interviewers were recognized as being ‘defacto’ staff of the clinic, to 
ensure that the screening and intervention were as ‘real world’ as possible.  All 
interviewers had some level of tertiary education within the field of health.  Within the 
Brazilian PHCs, both clinicians and researchers were used to recruit participants and 
conduct the study and were trained by the local study coordinators to administer the 
test battery, ASSIST and Brief Intervention. 
 
Primary Health Care clients were pre-screened for suitability in terms of their ASSIST 
score and around the exclusion/inclusion criteria.  Some PHC setting utilized a self-
completion version of the ASSIST as an initial pre-study screen (Australia and USA), 
while other sites approached and screened clients directly.  Participants who appeared 
to score within the desirable moderate risk range met the inclusion/exclusion criteria 
were recruited to the study under the proviso that they were eligible to participate.  
Participants were administered the ASSIST questionnaire and demographic profile by 
the interviewer and following enrolment into the study were randomized to either the 
waitlist Control or Intervention group and were assigned a unique identification number.  
Depending on their gender and the score received for a particular substance at 
baseline, participants in each group also were matched to a high use (scoring between 
16 and 27 for cannabis, cocaine, ATS or opioids) or low use substance group (scoring 
between 4 and 15 for cannabis, cocaine, ATS or opioids).  All participants gave their 
informed consent and were asked for contact information to arrange a follow-up 
interview.  
 
Intervention participants received the ASSIST-linked Brief Intervention including the 
associated self-help materials.  The Brief Intervention was timed and details of the Brief 
Intervention were recorded on a checklist (APPENDIX 8.3, “WHO ASSIST Brief 
Intervention Record”).  Control participants did not receive an intervention, but were 
told that they would be contacted again in three months, and to contact the clinical 
interviewer if they had concerns about the study or their substance use during this time.  
Both Control and Intervention participants had an appointment made by the researcher 
for the three month follow-up at the completion of the baseline session.  It is worth 
noting that baseline assessments were kept to a minimum because of the potential for 
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bias and disruption to the flow of routine medical consultation at the primary health care 
setting, although this did vary from country to country. 
 
At the three month follow-up, both groups (Control & Intervention) were re-administered 
the ASSIST and the Intervention participants were administered a brief intervention 
feedback questionnaire to ascertain perceptions of how the information and feedback 
they received at baseline had affected their drug use (APPENDIX 8.4, “WHO ASSIST 
Brief Intervention Process Rating Form – Follow up”).  Control participants received a 
brief intervention at this time.  
 
2.6 Ethical Approval 
Ethical approval for this study was obtained from the appropriate regulatory bodies in 
each country and all relevant ethical safeguards were met in relation to protection of 
participants.  Ethical approval was obtained from the following regulatory bodies: 
 
o Australia – Royal Adelaide Hospital board of ethics, South Australia 
o Brazil  
o Sao Paulo – Committee of Ethics on Research from the Federal 
University of São Paulo/Hospital São Paulo and Committee of Ethics on 
Research of Reference and Training on STD/AIDS from S.Paulo State. 
 
o Curitiba - Ethics Committee for Human Research of the Hospital de 
Clínicas da Universidade Federal do Parana. 
o India –Ethics Committee of the All India Institute of Medical Sciences, New Delhi 
o USA CA - UCLA Office for Protection of Research Subjects 
o USA Conn - Human Subjects Protections Office at the University of Connecticut 
Health Center  
 
Participants were given verbal and written information concerning the study and asked 
to sign consent forms.  Within the Australian, Brazilian and Indian sites the Information 
sheet was 1-2 pages and the consent procedure took a few minutes.  The USA sites 
had an alternative approach relating to the ethical requirements of the investigating 
institution.  Their required consent and HIPAA Authorization forms were 5 pages long 
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which needed to be read to participants.  This process took approximately 10-15 
minutes. 
 
2.7 Scores derived from the ASSIST questionnaire 
A number of scores derived from participants’ results on the ASSIST were used for 
analysis. The following scores at both baseline and follow-up were calculated from data 
collected: 
 
1. Total Illicit Substance Involvement Score (calculated by the addition of all 
responses to Questions 1-8 excluding alcohol and tobacco) 
 
∑ Q1c – j + Q2c - j + Q3c – j + Q4c – j  + Q5c – j + Q6c – j + Q7c – j + Q8 (Max Score: 336) 
 
2. Specific Substance Involvement Score for each Substance (calculated by the 
addition of responses to Questions 2-7 within each substance class).  This score 
indicates the extent of involvement with specific substances (tobacco, alcohol, 
cannabis, cocaine, ATS, inhalants, sedatives/sleeping pills, hallucinogens and opioids).  
NB. Q5. is not included for calculation of the Tobacco Specific Substance Involvement 
Score, however, all other Specific Substance Involvement Scores are calculated 
similarly (for example, see Alcohol Score below). 
 
∑ Q2a + Q3a + Q4a + Q6a + Q7a   (a = Tobacco, Max Score: 31) 
∑ Q2b + Q3b + Q4b + Q5 b + Q6b + Q7b   (b = Alcohol, Max Score: 39) 
 
 
2.8 Data Analysis 
2.8.1 Descriptive Statistics 
Descriptive statistics were obtained for the demographic characteristics of the pooled 
sample as well as for each country.  Substance involvement at baseline, ASSIST 
scores at baseline and average follow-up times also were calculated for the pooled and 
country by country data.  Where relevant, one-way ANOVA and Chi-square 
comparisons were used to detect differences between groups.  This also included the 
comparison of ASSIST scores between Control and BI participants at baseline. 
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2.8.2 Quantitative Analysis  
Two-way repeated measures ANOVA (General Linear Model or GLM) were utilized to 
assess the effectiveness of the Brief Intervention.  Comparisons of ASSIST scores at 
baseline and follow-up for both groups of participants (Control and BI) were conducted 
on several ASSIST substance scores (detailed below).  Amphetamine-type Stimulants 
and Cocaine Specific Substance Involvement Scores were collapsed into one category 
called Stimulant Specific Substance Involvement Scores to create an adequate sample 
size for comparison.   
 
Control participants (who did not receive the brief intervention at baseline) were 
included in the analysis to control for the effects of time and determine if there was a 
significant interaction effect.  GLM statistics were calculated for the total pooled sample 
(all countries), and also for each country where relevant.  Comparisons between 
countries were made initially with GLM and significant findings were further investigated 
with Tukey’s HSD post-hoc comparisons. 
 
Analysis was performed on the following scores and samples: 
 
• ASSIST Total Illicit Substance Involvement Scores; 
o For all participants from all countries (pooled) 
o Country by country (Australia, Brazil, India, USA) 
 
• ASSIST Specific Substance Involvement Scores for cannabis, stimulants (ATS 
and cocaine) and opioids*; 
o For all participants from all countries (pooled) 
o Country by country (Australia, Brazil, India, USA) 
o * India was the only country involved in an investigation of changes in 
the Opioid Specific Substance Involvement Score due to inadequate 
sample sizes in other countries. 
 
• ASSIST Specific Substance Involvement Scores for substances not targeted by a 
specific BI; 
o Tobacco and Alcohol Specific Substance Involvement Scores for all 
participants from all countries (pooled) 
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o Inhalant, Sedative and Hallucinogen Specific Substance Involvement 
Scores for all participants who scored positive (i.e., ≥1) for these 
substances at baseline from all countries (pooled) 
 
• Comparison of ‘high’ (16-26) and ‘low’ (4-15) scorers for the following domain 
scores; 
o Total Illicit Substance Involvement 
o Cannabis Specific Substance Involvement 
o Stimulant Specific substance Involvement 
o Quantitative Participant Feedback scores 
 
• Quantitative Participant Feedback; 
o For all participants from all countries (pooled) 
o Country by country (Australia, Brazil, India, USA) 
 
2.8.3 Thematic Analysis on Participant Feedback at follow-up 
A significant and innovative aspect of the responses resulting from ASSIST-screening, 
is that it allows personalized feedback to participants regarding their risk scores and 
the provision of information around their current patterns of use and the risks 
associated with those scores.  The scores also allow the clinician to engage the client 
in a non-confrontational way using client-centred techniques.  This is the essence of a 
good brief intervention.  This personalized feedback was specifically incorporated into 
the design of the ASSIST BI via the use of the ASSIST Feedback Report Card (See 
APPENDIX 8.2) to increase participants’ understanding of the relationship between 
their substance taking behaviour and their health outcomes.  
 
An integral aspect of this Phase III study was to investigate how participants perceived 
the feedback and information they had received and whether they had modified their 
attitude and substance use as a result.  In order to achieve this, feedback from 
participants receiving the brief intervention was incorporated to determine the 
effectiveness of the ASSIST BI. The ASSIST Brief Intervention Process Rating Form 
(see APPENDIX 8.4) was administered at follow-up three months after baseline.  This 
gave participants, who received a brief intervention at baseline, the opportunity to 
provide feedback on the process of the ASSIST-linked BI via a series of open-ended 
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questions and/or rating scales.  It is worth noting that participants were re-administered 
the ASSIST questionnaire prior to the Brief Intervention Process Rating Form.  The 
ASSIST Brief Intervention Process Rating Form focussed on three broad areas: 
 
1. General Information about participants’ perceptions of feedback and information 
provided as part of the process of the BI;  
2. Specific questions concerning the information and feedback received during the 
session with the interviewer, and  
3. Specific questions concerning the written take-home information provided in the 
Substance Users Guide.  
 
Descriptive statistics describing participants’ self-report rating scale outcomes 
ascertained from the Brief Intervention Process Rating are presented using descriptive 
statistics.  
 
Responses to each open-ended question (termed ‘data set’) were analysed using 
thematic analysis (Braun & Clarke, 2006).  Responses in each data set were examined 
to identify similarities and/or differences and were manually coded into key themes.  
Themes were considered ‘key’ when there was a repeated occurrence of terms and/or 
phrases within the corpus of responses.  More specifically, the patterned responses 
identified as key themes within each data set capture something important in relation to 
the research questions about the effectiveness of the BI.  Where applicable, these 
themes were discussed in conjunction with results from participants’ rating scales that 
formed part of the question.  Implications arising from these results also are discussed.  
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3. RESULTS 
 
3.1 Demographics 
A total of 731 participants were recruited for the international study (Australia n = 171; Brazil n = 
165; India n = 177; USA n = 218).  The USA site comprised participants combined from two 
different states; California (n=40) and Connecticut (n=178).   
 
Over two thirds (72.1%) of the sample were male (Australia 62%, Brazil 81%, India 100%, USA 
51%) and 72% of all participants were currently employed (Australia 77%, Brazil 60%, India 94%, 
USA 58%).  The mean age of participants was 31.4 (sd = 9.3) and ranged between 16 and 62 
years.  The mean number of years of education achieved by participants was 9.5 (sd = 5.2) and 
ranged from 0 to 22 years.  The variation in participants’ age and education levels by country is 
shown in Tables 1 and 2 respectively.   
 
Table 1.  Participants’ age in years by country (N=731) 
Country Mean Age (SD) years Min Max 
Australia 26.2 (6.0) 17 45 
Brazil 34.2 (9.6) 16 62 
India 33.4 (8.7) 18 50 
USA 31.7 (10.0) 18 58 
 
Table 2.  Participants’ education level in years by country (N=731) 
Country Mean education (SD) 
years 
Min Max 
Australia 13.4 (2.3) 9 20 
Brazil 9.5 (3.8) 1 22 
India 2.5 (3.6) 0 12 
USA 12.3 (2.0) 5 18 
 
Over half of the total sample had never been married (55.5%) with 34.1% either married 
or cohabiting.  There was some variation between countries with regards to the 
proportion of participants who had never been married.  Australian participants in this 
study were the least likely to be married (91.2%) followed by American participants 
(54.6%), Brazilian participants (58.8%) and Indian participants (18.8%).   
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The majority of the sample lived either in their own home or their own rented 
accommodation (93.7%) and this was the case for the majority of participants in all 
countries (range: USA 91.3% - Australia 96.5%). 
 
Just over one half of the participants identified themselves as white Caucasian (59.6%) 
followed by Indian (24.4%) or African (7.3%).  The remainder identified themselves as 
Mulatto (3.1%), Hispanic (2.2%), Asian/Pacific Islander (1.2%), Native American (0.4%), 
Aboriginal/Torres Strait Islander (0.3%) or ‘Other’ (1.5%).   
 
Around one third of participants (32.1%) reported having no religious preference, while 
another third reported having Christian (Protestant, Catholic or Orthodox Christian) 
beliefs (33.4%).  The remaining participants identified as being Hindu (23.1%), 
Muslim/Islamic (1.2%), Buddhist (0.4%) or did not identify with any of the religious 
preferences presented (9.7%).   
 
The variation in participants’ race and religious preference by country is shown in 
Tables 3 and 4 respectively.   
 
Table 3.  Participants’ religious preference by country 
 Australia % Brazil % India % USA % 
Christian 
beliefs 
24.0 48.4 0.6 55.9 
Hindu 0 0 95.5 0 
Buddhist 0.6 0.6 0 0.5 
Muslim/Islamic 0.6 0 4.0 0.5 
Not religious 70.2 26.1 0 33.0 
Other religious 4.7 24.8 0 10.1 
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Table 4.  Participants’ race by country 
 Australia % Brazil % India % USA % 
White Caucasian 94.7 79.4 0 65.6 
Indian 0 0.6 100 0 
Asian/Pacific 
Islander 
3.5 0 0 1.4 
Hispanic 0 1.2 0 6.4 
Aboriginal/Torres 
Strait Islander 
1.2 0 0 0 
African 0 1.8 0 22.9 
Native American 0 0 0 1.4 
Mulatto 0 13.9 0 0 
Other race 0.6 3.0 0 2.3 
 
Fifteen per cent (15%) of participants had received treatment for drug or alcohol 
problems (excluding nicotine) at some stage in their lives (Australia 8.8%, Brazil 18.2%, 
India 0%, USA 29.8%) and the mean time since receiving the treatment was 3.8 years 
(sd=4.9) previously.  Participants had most frequently received treatment for problems 
related to the use of cocaine (4.5%), alcohol (4.0%), cannabis (2.6%), ATS (1.8%), 
opioids (1.2%), hallucinogens (0.4%) or ‘another drug’ (0.5%), and treatment was most 
likely to be counselling (6.6%) followed by residential rehabilitation (3.3%), assisted 
detoxification (2.5%), a twelve step program (1.5%) or pharmacotherapy (0.7%). 
 
 
3.1.1 Treatment at baseline  
All participants were randomized into two groups at baseline.  The 372 participants who 
were randomly allocated to the BI group (50.9%) received a drug-specific BI at baseline 
and the 359 (49.1%) randomized to the wait list Control Group received a BI at follow 
up (approximately three months later).  A total of 395 participants were in the cannabis 
group, 92 in the cocaine group, 155 in the ATS group and 89 were in the opioids group.  
Table 5 shows the variation between countries in the types of substance user recruited 
to the study. 
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Table 5.  Substance group by country 
 Australia Brazil India USA Total 
Cannabis 31 112 106 146 395 
Cocaine 9 45 0 38 92 
ATS 129 8 0 18 155 
Opioids 2 0 71 16 89 
Total 171 165 177 218 731 
 
Participants in each group also were allocated to a ‘high’ or ‘low’ use substance group 
depending on their gender and the score received for a particular substance at 
baseline.  They were then randomized to get a brief intervention or wait list control.  
That is, participants scoring between 4 and 16 were allocated to the ‘low score’ 
category and those scoring 17-26 were allocated to the ‘high score’ category.  
However, it is worth noting that all these participants still were considered to be at 
‘moderate risk’ from their substance use.  Table 6 below summarises the distribution of 
male and female participants across the high/low substance use in both the Brief 
Intervention and Control Groups.   
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Table 6.  Substance Group Randomization n (%) within total sample (N=731) 
 Frequency of High or Low scorers by gender 
 
Male High 
47.2% 
Male Low 
24.9% 
Female High 
14.9% 
Female Low 
13.0% 
Sub-
total 
Total 
Cannabis 
BI 
102 58 28 24 212 
Cannabis 
Control 
85 47 23 28 183 
395  
(54.0%) 
Cocaine 
BI 
20 11 7 6 44 
Cocaine 
Control 
14 23 9 2 48 
92  
(12.6) 
ATS BI 23 19 17 15 74 
ATS 
Control 
23 23 18 17 81 
155 
(21.2%) 
Opioids BI 38 0 3 1 42 
Opioids 
Control 
40 1 4 2 47 
89 
(12.2%) 
Total 527 (72.1%) 204 (27.9%) 731 
731 
(100%) 
 
3.1.2 Follow-up 
It was intended that the period of time between baseline and follow-up interviews be 3 
months (approximately 90 days).  The average reported period of time between the 
baseline and follow-up interview was between three and four months (mean = 104.7 
days, sd = 30.9, median 95 days).  The time between the two interviews ranged from 
approximately one month (32 days) to over one year (435 days) for the total sample, 
although there was some variation between the sites.  A total of 628 participants were 
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followed up (86%) and the remainder were lost to follow-up.  Table 7 shows the 
variation in follow-up times and follow-up rates by country. 
 
Table 7.  Number of days between baseline and follow-up interview by country 
and follow-up rates by country 
 
Follow-up 
rate (%) 
Mean (sd) 
days Median days Min days Max days 
Australia 94.7 101.7  (14.7) 97.0 80 158 
Brazil 86.7 113.1  (24.9) 110.0 83 210 
India 87.6 95.9  (7.8) 94.0 78 132 
USA 77.1 106.9  (51.3) 92.0 32 435 
 
 
3.1.3 Substance Involvement at Baseline 
Alcohol, cigarettes and cannabis were the substances most likely to have been used 
ever, and to have received a positive Specific Substance Involvement Score by this 
sample, followed by ATS and cocaine.  Gamma-hydroxybutyrate (GHB or ‘Fantasy’) 
was the substance most frequently reported (3.1%) under ‘other drugs’.  ASSIST scores 
obtained by the sample are shown in Table 8.  These scores were calculated only for 
participants who scored positive (i.e. at least one) for the specific substance concerned.  
With regard to individual substances, the highest average score was for tobacco 
followed by ATS then cannabis and alcohol.  Table 9 shows country by country 
variation of the frequency of participants scoring positive for the main illicit substances 
of interest (cannabis, cocaine, ATS and opioids) and tobacco and alcohol, as well as 
the respective ASSIST SSI scores obtained.   
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Table 8.  Frequency of lifetime substance use and positive SSI scores for a 
substance and respective ASSIST scores obtained (N=731) 
Specific  
Substance  
Q1. Ever Used 
Lifetime N (%) 
N (%) scoring +ve for 
substance (SSI)  
ASSIST SSI mean 
score (SD) 
Tobacco 707   (96.7) 622   (85.1) 17.0  (10.0) 
Alcohol 715   (97.8) 634   (86.7) 12.0  (9.2) 
Cannabis 706   (96.6) 617   (84.4) 13.2  (9.2) 
Cocaine 373   (51.0) 216   (29.5) 3.2  (6.9) 
ATS 323   (44.2) 215   (29.4) 3.9  (7.4) 
Inhalants 208   (28.5) 50   (6.8) 0.3  (2.0) 
Sedatives 237   (32.4) 97   (13.3) 1.3  (4.6) 
Hallucinogens 292   (39.9) 85   (11.6) 0.6  (2.1) 
Opioids 232   (31.7) 147   (20.1) 3.5  (7.9) 
Other  37   (5.1) 12   (1.6) 0.1  (0.7) 
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Table 9.  Frequency of positive SSI scores and respective ASSIST scores obtained 
for cannabis, cocaine, ATS, opioids, tobacco and alcohol by country 
 Australia n=171 Brazil n = 165 India n=177 USA n=218 
 
n (%) 
scoring 
+ve 
SSI 
score 
(sd) 
n (%) 
scoring 
+ve 
SSI 
score 
(sd) 
n (%) 
scoring 
+ve 
SSI 
score 
(sd) 
n (%) 
scoring 
+ve 
SSI 
score 
(sd) 
Cannabis 
143  
(83.6) 
12.7  
(8.6) 
140  
(84.8) 
12.8  
(6.9) 
136  
(76.8) 
22.1  
(2.6) 
198  
(90.8) 
15.4  
(7.8) 
Cocaine 
61  
(35.7) 
5.2  
(4.4) 
71  
(43.0) 
10.9  
(8.0) 
0 0 
84  
(38.5) 
14.9  
(10.0) 
ATS 
152  
(88.9) 
14.6  
(7.5) 
19  
(11.5) 
7.4  
(6.3) 
0 0 
44  
(20.2) 
9.9  
(7.2) 
Opioids 
17  
(9.9) 
6.1  
(7.1) 
1   (0.6) 
3.0      
( - ) 
84  
(47.5) 
22.1  
(3.2) 
45  
(20.6) 
12.9  
(9.4) 
Tobacco 
142  
(83) 
18.7  
(8.7) 
127  
(80.0) 
18.2  
(8.5) 
176  
(99.4) 
23.1  
(2.7) 
177  
(81.2) 
19.3  
(8.6) 
Alcohol 
169  
(98.8) 
12.6  
(7.8) 
144  
(87.3) 
10.8  
(8.8) 
124  
(70.0) 
19.1  
(3.4) 
197  
(90.4) 
13.9  
(9.6) 
 
The mean Total Illicit Substance Involvement Score at baseline for the total sample was 
36.2 (SD = 19.4, n = 731).  Participants from Australia had the highest Total Illicit 
Substance Involvement Score at baseline (45.2, sd=18.9) followed by those from the 
USA (37.1, sd=23.6), India (34.7, sd=14.3) and Brazil (27.2, sd=13.5).  These scores 
were significantly different overall (F (3,726) = 27.2, p<0.001). 
 
The majority (N= 628, 86%) of participants had never injected any substance.  Of the 
remaining participants who had injected drugs in their lifetime, twenty three (3.2%) 
reported injecting within the past three months.   
 
3.1.3.1 Current Frequency of Substance Involvement  
The substances most frequently used (Q2) by the total sample of participants in the last 
three months were alcohol, followed by tobacco, cannabis, ATS, cocaine and opioids 
(Table 10 below).  
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Table 10.  Frequency of Substance use over last 3 months (Q2) (N=731). 
 Frequency N (%) of use in last 3 months (Q2) 
 Never 
Once or 
Twice 
Monthly Weekly 
Daily / 
Almost daily 
Tobacco 140  (19.2) 29  (4.0) 14  (1.9) 44  (6.0) 504  (68.9) 
Alcohol 121  (16.6) 100  (13.7) 124  (17.0) 299  (40.9) 87  (11.9) 
Cannabis 147  (20.1) 54  (11.5) 94  (12.9) 153  (20.9) 253  (34.6) 
Cocaine 571  (78.1) 73  (10.0) 48  (6.6) 35  (4.8) 4  (0.5) 
ATS 543  (74.3) 55  (7.5) 75  (10.3) 55  (7.5) 3  (0.4) 
Inhalants 700  (95.8) 24  (3.3) 4  (0.5) 2  (0.3) 1  (0.1) 
Sedatives 648  (88.6) 32  (4.4) 20  (2.7) 23  (3.1) 8  (1.1) 
Hallucinogens 683  (93.4) 35  (4.8) 11  (1.5) 2  (0.3) 0 
Opioids 605  (82.8) 19  (2.6) 23  (3.1) 21  (2.9) 63  (8.6) 
Other 728  (99.6) 2  (0.3) 1  (0.1) 0 0 
 
3.1.3.2 Comparison of substance use at baseline by Brief Intervention and Control 
groups 
There were no significant differences between BI and Control groups at baseline with 
respect to their Total Illicit Substance Involvement Scores (p=0.73), Tobacco SSI 
(p=0.43), Alcohol SSI (p=0.90), Cannabis SSI (p=0.19), Cocaine SSI (p=0.92), ATS SSI 
(p=0.53), Inhalant SSI (p=0.57), Sedative SSI (p=0.20), Hallucinogen SSI (p=0.98), 
Opioid SSI (p=0.98) or ‘Other drug’ SSI (p=0.99).  There was no significant difference in 
injecting behaviour between BI and Control subjects (Chi squared=0.99, p=0.61). 
 
3.1.3.3 Administration Times 
Table 11 below shows the average time taken to administer the ASSIST questionnaire 
and BI respectively at baseline and at follow-up.  Tables 12 and 13 show the respective 
times taken by each country for administration of the baseline ASSIST and BI.  There 
were significant differences in the overall time taken to administer the ASSIST 
(p<0.001) and BI (p<0.001) between countries. 
 
WHO ASSIST Phase III Technical Report  
 41 
Table 11.  Time (minutes) to administer the ASSIST Questionnaire and Brief 
Intervention at Baseline and Follow-up 
 
 
Mean (SD) Median Min Max 
ASSIST Baseline (N = 702) 7.9  (3.7) 7 3 60 
ASSIST Follow-up (N = 631) 6.7  (3.2) 5 1 25 
BI Baseline (N = 369) 13.8  (8.5) 11 3 60 
BI Follow-up (N = 285) 11.3  (6.9) 10 1 40 
 
Table 12.  Time (minutes) to administer the ASSIST questionnaire at baseline by 
country 
 Mean (sd) Median Min Max 
Australia n=171 8.3  (2.4) 8 4 17 
Brazil n=165 7.2  (3.7) 5 3 25 
India n=177 6.6  (1.9) 6 4 12 
USA n=189 9.3  (5.0) 10 3 60 
 
Table 13.  Time (minutes) to administer the BI at baseline by country 
 Mean (sd) Median Min Max 
Australia n=83 7.7  (2.1) 8 3 15 
Brazil n=94 23.3  (10.9) 20 8 60 
India n=89 10.9  (1.6) 11 7 15 
USA n=103 12.7  (4.7) 12 4 30 
 
 
WHO ASSIST Phase III Technical Report  
 42 
3.2 Inferential Statistical Analysis  
3.2.1 Effect of the ASSIST BI on Total Illicit Substance Involvement Score 
3.2.1.1 Pooled data (N=628) 
All participants were included in the analysis, regardless of the substance targeted in 
the intervention (n = 628).  Assumptions of normality, homogeneity of variance and 
sphericity were met.  Two-way repeated measures ANOVA results showed that there 
was a significant reduction over time (F(1,626) = 117.5, p<0.001) regardless of group.  
Moreover, there was a significant interaction effect and the group receiving the Brief 
Intervention at baseline had significantly lower mean Total Illicit Substance Involvement 
scores at follow-up compared with the Control group (Table 14, F(1,626) = 7.2, p<0.01, 
observed power 76.4%, alpha=0.05).  Results are shown graphically in Figure 1 below. 
 
Table 14.  Total Illicit Substance Involvement Scores – BI and Control at Baseline 
and Follow-up (N=628) – Pooled data. 
 Baseline Score  (SD) Follow-up Score  (SD) 
Control Group (n=306) 36.9   (20.1) 32.3   (17.9) 
Brief Intervention (n=322) 36.7   (19.0) 28.9   (17.3) 
 
A similar interaction effect was observed when the two-way repeated measures ANOVA 
was re-calculated controlling for age and education (F(1,624) = 7.6, p<0.01, observed 
power = 78.4%) however, neither age nor education appeared to have a significant 
impact on the outcome (p=0.15 and p=0.85 respectively). 
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Figure 1.  Total Illicit Substance Involvement scores over time, BI vs. Control 
(N=628) – Pooled data. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.2.1.2 Country by Country 
 
 
 
All participants were included in the analysis for each country, regardless of the 
substance targeted in the intervention.  Assumptions of normality, homogeneity of 
variance and sphericity were met.  Two-way repeated measures ANOVA results showed 
there was a significant reduction over time for each country regardless of group 
(Australia: F(1,160) = 25.0, p<0.001;  Brazil: F(1,141) = 29.8, p<0.001;  India: F(1,153) 
= 66.5, p<0.001;  USA: F(1,166) = 23.2, p<0.001).   
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There was a significant interaction effect for all countries with the exception of the USA.  
Table 15 shows Total Illicit substance Involvement Scores for each country and that the 
participants receiving the Brief Intervention in Australia, Brazil and India had 
significantly reduced Total Substance Involvement Scores at follow-up compared with 
Control subjects.  Tukey’s HSD post hoc comparisons of mean differences in Total Illicit 
Substance Involvement scores between each respective country are shown in Table 16.  
The table shows that there were significant differences between countries with respect 
to the change in Total Illicit Substance Involvement scores over time.   
 
Table 15.  Total Illicit Substance Involvement Scores – BI and Control at Baseline 
and Follow-up by country 
  Baseline 
Score (SD) 
Follow-up 
Score (SD) 
Interaction 
effect  p  
Power Interaction by 
country  p  
Control 
(n=80) 
43.4   (18.7) 42.3   (20.3) 
Australia 
BI          
(n=82) 
47.2   (19.4) 39.0   (17.8) 
F = 14.68,  
p<0.001 
97% 
Control  
(n=60) 
25.6   (12.2) 23.2   (12.2) 
Brazil 
BI         
(n=83) 
29.3   (14.3) 20.9   (13.5) 
F = 9.1,  
p<0.005 
85% 
Control  
(n=77) 
34.5   (14.9) 30.4   (13.4) 
India 
BI         
(n=78) 
34.5   (13.9) 25.2   (12.3) 
F = 10.0,  
p<0.005  
85% 
Control  
(n=89) 
40.9   (25.4) 31.0   (18.1) 
USA 
BI         
(n=79) 
35.6   (22.6) 30.6   (19.2) 
F = 2.5,  
p=0.11  
35% 
F = 6.4, 
p<0.001 
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Table 16.  Post hoc comparisons of mean differences in Total Illicit Substance 
Involvement Scores between countries 
 Australia Brazil India USA 
Australia 
Mean difference 
(p value) 
 
na 
 
-18.2 
(p<0.001) 
 
-11.8 
(p<0.001) 
 
-8.4   
(p<0.001) 
Brazil 
Mean difference 
(p value) 
 
18.2  
(p<0.001) 
 
na 
 
6.4    
(p<0.005) 
 
9.8    
(p<0.001) 
India 
Mean difference 
(p value) 
 
11.8  
(p<0.001) 
 
-6.4   
(p<0.005) 
 
na 
 
3.4      
(p=0.22) 
USA 
Mean difference 
(p value) 
 
8.4    
(p<0.001) 
 
-9.8   
(p<0.001) 
 
-3.4    
(p=0.22) 
 
na 
 
3.2.3 Effect of the ASSIST BI on Cannabis Specific Substance Involvement Score  
 
3.2.3.1 Pooled data (N=328) 
Participants included in this analysis were those from all countries randomized to 
receive BI for cannabis involvement at baseline (n=176), and those randomized to the 
Control Group for cannabis involvement at follow-up (n=152).  Assumptions of 
normality, homogeneity of variance and sphericity were met.  Two-way repeated 
measures ANOVA results showed that there was a significant reduction over time 
(F(1,326) = 51.2, p<0.001) regardless of group.  Moreover, there was a significant 
interaction effect and the group receiving the Brief Intervention at baseline had 
significantly lower mean Cannabis Specific Substance Involvement scores at follow-up 
compared with the Control group (Table 17, F(1,326) = 4.2, p<0.05, observed power 
53%, alpha=0.05).  Results are shown graphically in Figure 2 below.  
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Table 17.  Cannabis Specific Substance Involvement Scores – BI and Control at 
Baseline and Follow-up (N=328) 
 Baseline Score  (SD) Follow-up Score  (SD) 
Control Group (n=152) 17.8   (6.7) 15.7   (8.1) 
Brief Intervention (n=176) 17.6   (7.0) 13.9   (9.0) 
 
Figure 2.  Cannabis Specific Substance Involvement scores over time, BI vs. Control 
(N=328) – Pooled data. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.2.3.2 Country by Country 
All participants in the cannabis group were included in the analysis for each country.  
Assumptions of normality, homogeneity of variance and sphericity were met.  Two-way 
repeated measures ANOVA results showed there was a significant reduction over time 
for each country regardless of group (Australia: F(1,28) = 4.0, p=0.05;  Brazil: F(1,90) = 
9.0, p<0.005;  India: F(1,96) = 20.2, p<0.001;  USA: F(1,106) = 19.5, p<0.001).   
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There was a significant interaction effect for Brazil and India, but not Australia or the 
USA.  Table 18 shows the respective Cannabis Substance Involvement Scores for each 
country and that the participants receiving the Brief Intervention in Brazil and India had 
significantly reduced Cannabis Specific Substance Involvement Scores at follow-up 
compared with Control subjects.  Tukey’s HSD post hoc comparisons of mean 
differences in Cannabis Specific Substance Involvement scores between each 
respective country are shown in Table 19. 
 
Table 18.  Cannabis Specific  Substance Involvement Scores – BI and Control at 
Baseline and Follow-up by country 
  Baseline 
Score (SD) 
Follow-up 
Score (SD) 
Interaction 
effect         
p value 
Power Interaction 
by country  
p value 
Control 
(n=13) 
19.1   (7.8) 18.7   (7.9) 
Australia 
BI          
(n=17) 
20.2   (5.3) 17.2   (6.2) 
F = 24.07,  
p = 0.137 
31% 
Control  
(n=35) 
12.1   (5.9) 12.1   (7.4) 
Brazil 
BI         
(n=57) 
13.1   (6.2) 8.3   (7.8) 
F = 9.0,  
p<0.005 
84% 
Control  
(n=49) 
22.3   (2.6) 21.7   (5.0) 
India 
BI         
(n=49) 
22.9   (1.9) 18.7   (6.3) 
F = 11.7,  
p<0.005  
92% 
Control  
(n=55) 
17.0   (6.6) 11.9   (7.3) 
USA 
BI         
(n=53) 
16.6   (7.8) 14.3   (10.1) 
F = 2.7,  
p=0.105  
37% 
F = 5.5, 
p<0.005 
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Table 19.  Post hoc comparisons of mean differences in Cannabis Specific 
Substance Involvement Scores between countries 
 Australia Brazil India USA 
Australia 
Mean difference 
(p value) 
 
na 
 
-7.6    
(p<0.001) 
 
2.6      
(p=0.12) 
 
-3.8      
(p<0.01) 
Brazil 
Mean difference 
(p value) 
 
7.6    
(p<0.001) 
 
na 
 
10.1   
(p<0.001) 
 
3.7    
(p<0.001) 
India 
Mean difference 
(p value) 
 
-2.6    
(p=0.12) 
 
-10.1   
(p<0.001) 
 
na 
 
-6.4    
(p<0.001) 
USA 
Mean difference 
(p value) 
 
3.8      
(p<0.01) 
 
-3.7   
(p<0.001) 
 
6.4    
(p<0.001) 
 
na 
 
3.2.4 Effect of the ASSIST BI on Stimulant Specific Substance Involvement Scores 
(Amphetamine-Type Stimulants and cocaine) 
3.2.4.1 Pooled data (N=229) 
Participants included were those from all countries randomized to receive BI for either 
cocaine or ATS at baseline (n=110), and those randomized to the Control Group for 
cocaine or ATS involvement at follow-up (n=119).  Assumptions of normality, 
homogeneity of variance and sphericity were met.  Two-way repeated measures 
ANOVA results showed that there was a significant reduction over time (F(1,227) = 
95.6, p<0.001) regardless of group.  Moreover, there was a significant interaction effect 
and the group receiving the Brief Intervention at baseline had significantly lower mean 
Stimulant Substance Involvement scores at follow-up compared with the Control group 
(Table 20, F(1,227) = 9.4, p<0.005, observed power 86%, alpha=0.05).  Results are 
shown graphically in Figure 3 below.   
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Table 20.  Stimulant Specific Substance Involvement Scores (ATS and cocaine) – 
BI and Control at Baseline and Follow-up (N=229) 
 Baseline Score  (SD) Follow-up Score  (SD) 
Control Group (n=119) 15.3   (7.3) 12.1   (8.6) 
Brief Intervention (n=110) 17.3   (7.4) 11.1   (8.6) 
 
 
Figure 3.  Stimulant (cocaine & ATS) Specific Substance Involvement scores over 
time, BI vs. Control (N=229) – Pooled data. 
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3.2.4.2 Country by Country  
All participants in the stimulant groups (cocaine and ATS) were included in the analysis 
for each country where relevant.  Assumptions of normality, homogeneity of variance 
and sphericity were met.  Two-way repeated measures ANOVA results showed there 
was a significant reduction over time for each country (excluding India which did not 
recruit any stimulant users) regardless of group (Australia: F(1,128) = 41.4, p=0.05;  
Brazil: F(1,49) = 33.3, p<0.001;  USA: F(1,46) = 22.1, p<0.001).   
 
There was a significant interaction effect for Australia and Brazil, but not the USA.  
Table 21 shows the respective Stimulant (cocaine & ATS) Substance Involvement 
Scores for each country and that the participants receiving the Brief Intervention in 
Australia and Brazil had significantly reduced Stimulant Substance Involvement Scores 
at follow-up compared with Control subjects.  Tukey’s HSD post hoc comparisons of 
mean differences in Stimulant Specific Substance Involvement scores between each 
respective country (excluding India) are shown in Table 22. 
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Table 21.  Stimulant Specific Substance Involvement Scores (cocaine and ATS) – 
BI and Control at Baseline and Follow-up by country 
  Baseline 
Score (SD) 
Follow-up 
Score (SD) 
Interaction 
effect         
p value 
Power Interaction 
by country  
p value 
Control 
(n=66) 
15.4   (6.9) 13.5   (7.9) 
Australia 
BI          
(n=64) 
16.8   (7.2) 11.7   (7.3) 
F = 8.7,  
p<0.005 
84% 
Control  
(n=25) 
11.2   (6.1) 7.7   (6.2) 
Brazil 
BI         
(n=26) 
16.0   (6.8) 6.5   (5.8) 
F = 7.2,  
p<0.01 
75% 
Control  
(n=0)  
na na 
India 
BI      
(n=0) 
na na 
NA NA 
Control  
(n=28) 
18.6   (7.6) 12.6   (10.9) 
USA 
BI         
(n=20) 
20.7   (8.4) 15.3   (12.4) 
F = 0.1,  
p=0.73  
6% 
F = 2.9, 
P=0.06 
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Table 22.  Post hoc comparisons of mean differences in Stimulant Specific 
Substance Involvement Scores between countries 
 Australia Brazil India USA 
Australia 
Mean difference 
(p value) 
 
na 
 
-4.0    
(p<0.001)) 
 
na 
 
2.3      
(p=0.11) 
Brazil 
Mean difference 
(p value) 
 
4.0    
(p<0.001) 
 
na 
 
na 
 
6.3    
(p<0.001) 
India 
Mean difference 
(p value) 
 
na 
 
na 
 
na 
 
na 
USA 
Mean difference 
(p value) 
 
-2.3      
(p=0.11) 
 
-6.3   
(p<0.001) 
 
na 
 
na 
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3.2.5 Effect of the ASSIST BI on Opioid Specific Substance Involvement Scores 
3.2.5.1 Pooled data (N=73) 
Participants included were those from all countries randomized to receive BI for opioids 
at baseline (n=37), and those randomized to the Control Group for opioids at follow-up 
(n=36).  Assumptions of normality, homogeneity of variance and sphericity were met.  
Two-way repeated measures ANOVA results showed that there was a significant 
reduction over time (F(1,71) = 49.4, p<0.001) regardless of group.  The interaction 
effect was not significant in this case although it appeared there was a tendency for the 
group receiving the Brief Intervention at baseline to have lower mean Opioid Substance 
Involvement scores at follow-up compared with the Control group (Table 23, F(1,71) = 
3.4, p=0.07, observed power 45%, alpha=0.05).  Results are shown graphically in 
Figure 4 below.   
 
Table 23.  Opioid Specific Substance Involvement Scores – BI and Control at 
Baseline and Follow-up (N=73) 
 Baseline Score  (SD) Follow-up Score  (SD) 
Control Group (n=36) 21.9   (3.8) 16.3   (9.4) 
Brief Intervention (n=37) 22.7   (3.5) 13.1   (8.9) 
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Figure 4.  Opioid Specific Substance Involvement scores over time, BI vs. Control 
(N=73) – Pooled data.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.2.5.2 Country by Country  
Only participants from the Indian site were included in any analysis because other sites 
had recruited either very small or zero numbers of opioid users (Australia = 2; Brazil = 
0, USA = 16).  Assumptions of normality, homogeneity of variance and sphericity were 
met.  Two-way repeated measures ANOVA results showed there was a significant 
reduction over time for India regardless of group (F(1,56) = 57.2, p<0.001).  There was 
a significant interaction effect for India and Table 24 shows the respective Opioid 
Substance Involvement Scores for India and that the participants receiving the Brief 
Intervention had significantly reduced Opioid Substance Involvement Scores at follow-
up compared with Control subjects (F(1,56) = 6.9, p<0.05). 
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Table 24.  Opioid Specific Substance Involvement Scores – BI and Control at 
Baseline and Follow-up for India 
 
 Baseline Score  (sd) Follow-up Score  (sd) 
Control Group (n=28) 22.4   (2.4) 16.9   (8.3) 
Brief Intervention (n=30) 22.9   (2.0) 11.5   (8.2) 
 
 
3.2.6 Effect of the ASSIST BI on other substances 
 
3.2.6.1 Tobacco Specific Substance Involvement Score, Pooled data (N=631) 
All participants were included in the analysis, regardless of the substance targeted in 
the intervention (n = 631).  Assumptions of normality, homogeneity of variance and 
sphericity were met.  Two-way repeated measures ANOVA results showed that there 
was a significant reduction over time (F(1,629) = 117.5, p<0.05) regardless of group, 
but not a significant interaction effect.  Participants receiving the BI for illicit drugs did 
not have significantly higher or lower Tobacco Specific Substance Involvement Scores 
at follow-up in comparison with their Control counterparts (Table 25, F(1,629) = 1.2, 
p=0.28).  Results are shown graphically in Figure 5 below. 
 
Table 25.  Tobacco Specific Substance Involvement Scores – BI and Control at 
Baseline and Follow-up (N=631) – Pooled data. 
 Baseline Score  (SD) Follow-up Score  (SD) 
Control Group (n=308) 17.5   (10.1) 17.2   (10.0) 
Brief Intervention (n=323) 16.8   (10.0) 16.0   (10.0) 
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Figure 5.  Tobacco Specific Substance Involvement scores over time, BI vs. Control 
(N=631) – Pooled data. 
 
 
 
3.2.6.2 Alcohol Specific Substance Involvement Score, Pooled data (N=630) 
All participants were included in the analysis, regardless of the substance targeted in 
the intervention (n = 630).  Assumptions of normality, homogeneity of variance and 
sphericity were met.  Two-way repeated measures ANOVA results showed that there 
was a significant reduction over time (F(1,628) = 59.8, p<0.001) regardless of group, 
but not a significant interaction effect.  Participants receiving the BI for illicit drugs did 
not have significantly higher or lower Alcohol Specific Substance Involvement Scores at 
follow-up in comparison with their Control counterparts (Table 26, F(1,628) = 3.4, 
p=0.07).  Results are shown graphically in Figure 6 below. 
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Table 26.  Alcohol Specific Substance Involvement Scores – BI and Control at 
Baseline and Follow-up (N=630) – Pooled data. 
 Baseline Score  (SD) Follow-up Score  (SD) 
Control Group (n=308) 12.4   (9.3) 10.7   (8.6) 
Brief Intervention (n=322) 12.1   (9.0) 9.3   (8.3) 
 
Figure 6.  Alcohol Specific Substance Involvement scores over time, BI vs. 
Control (N=630) – Pooled data. 
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3.2.6.3 Inhalant Specific Substance Involvement Score, Pooled data (N=47) 
All participants who scored positive for inhalants at baseline (ie. >1) were included in 
the analysis, regardless of the substance targeted in the intervention (n = 47).  
Assumptions of normality, homogeneity of variance and sphericity were met.  Two-way 
repeated measures ANOVA results showed that there was a significant reduction over 
time (F(1,45) = 15.1, p<0.001) regardless of group, but not a significant interaction 
effect.  Participants receiving the BI for illicit drugs did not have significantly higher or 
lower Inhalant Specific Substance Involvement Scores at follow-up in comparison with 
their Control counterparts (Table 27, F(1,45) = 0.3, p=0.61).  Results are shown 
graphically in Fig 7 below. 
 
 
Table 27.  Inhalant Specific Substance Involvement Scores – BI and Control at 
Baseline and Follow-up (N=47) – Pooled data. 
 Baseline Score  (SD) Follow-up Score  (SD) 
Control Group (n=19) 5.7   (6.9) 3.7   (7.1) 
Brief Intervention (n=28) 4.9   (5.3) 2.3   (2.7) 
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Figure 7.  Inhalant Specific Substance Involvement scores over time, BI vs. 
Control (N=47) – Pooled data. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.2.9.1 Sedative Specific Substance Involvement Score, Pooled data (N=90) 
 
 
3.2.6.4 Sedative Specific Substance Involvement Score, Pooled data (N=90) 
All participants who scored positive for sedatives at baseline (ie. >1) were included in 
the analysis, regardless of the substance targeted in the intervention (n = 90).  
Assumptions of normality, homogeneity of variance and sphericity were met.  Two-way 
repeated measures ANOVA results showed that there was a significant reduction over 
time (F(1,88) = 53.3, p<0.001) regardless of group, but not a significant interaction 
effect.  Participants receiving the BI for illicit drugs did not have significantly higher or 
lower Sedative Specific Substance Involvement Scores at follow-up in comparison with 
their Control counterparts (Table 28, F(1,88) = 0.2, p=0.7).  Results are shown 
graphically in Figure 8 below. 
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Table 28.  Sedative Specific Substance Involvement Scores – BI and Control at 
Baseline and Follow-up (N=90) – Pooled data. 
 Baseline Score  (SD) Follow-up Score  (SD) 
Control Group (n=46) 10.0   (8.9) 4.3   (6.5) 
Brief Intervention (n=44) 8.8   (6.9) 2.9   (6.0) 
 
Figure 8.  Sedative Specific Substance Involvement scores over time, BI vs. 
Control (N=90) – Pooled data. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Control n=46 
BI n=44 
3 month FUBaseline
Time
12
10
8
6
4
2
S
e
d
a
ti
v
e
 S
p
e
c
if
ic
 s
u
b
s
ta
n
c
e
 I
n
v
o
lv
e
m
e
n
t 
S
c
o
re
Control n=46 
BI n=44 
WHO ASSIST Phase III Technical Report  
 61 
3.2.6.5 Hallucinogen Specific Substance Involvement Score, Pooled data (N=76) 
All participants who scored positive for hallucinogens at baseline (ie. >1) were included 
in the analysis, regardless of the substance targeted in the intervention (n = 76).  
Assumptions of normality, homogeneity of variance and sphericity were met.  Two-way 
repeated measures ANOVA results showed that there was a significant reduction over 
time (F(1,74) = 29.4, p<0.001) regardless of group, but not a significant interaction 
effect.  Participants receiving the BI for illicit drugs did not have significantly higher or 
lower Hallucinogen Specific Substance Involvement Scores at follow-up in comparison 
with their Control counterparts (Table 29, F(1,74) = 0.1, p=0.7).  Results are shown 
graphically in Figure 9 below. 
 
Table 29.  Hallucinogen Specific Substance Involvement Scores – BI and Control 
at Baseline and Follow-up (N=76) – Pooled data. 
 Baseline Score  (SD) Follow-up Score  (SD) 
Control Group (n=37) 5.2   (4.3) 2.2   (2.2) 
Brief Intervention (n=39) 4.7   (4.7) 2.1   (3.0) 
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Figure 9.  Hallucinogen Specific Substance Involvement scores over time, BI vs. 
Control (N=76) – Pooled data. 
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3.2.7 Effect of group (high or low scoring) on ASSIST scores 
 
3.2.7.1 Total Illicit Substance Involvement 
An initial two-way repeated measures ANOVA analysis comprising experimental 
condition (BI or Control) severity level (high/low), gender and country was calculated 
where the latter three factors were included in the analysis as covariates.  The results 
showed that there was a significant interaction effect (F(1,623) = 7.1, p<0.01, power = 
76%).  Gender and country did not have a significant impact on the outcome (p=0.86 
and p=0.25 respectively) however, severity (high/low) did have a significant impact 
(p<0.001) and this was investigated in two discrete analyses below. 
 
All participants allocated to the high scoring group (ie. scoring between 16 and 26) 
were included in the analysis, regardless of the substance targeted in the intervention 
(n = 393).  Assumptions of normality, homogeneity of variance and sphericity were met.  
Two-way repeated measures ANOVA results showed that there was a significant 
reduction over time (F(1,391) = 109.6, p<0.001) regardless of group.  Moreover, there 
was a significant interaction effect and the group receiving the Brief Intervention at 
baseline had significantly lower mean Total Illicit Substance Involvement scores at 
follow-up compared with the Control group (Table 30, F(1,391) = 4.2, p<0.05).   
 
Table 30.  Total Illicit Substance Involvement Scores for high scoring 
participants– BI and Control at Baseline and Follow-up (N=393) – 
Pooled data. 
 Baseline Score  (SD) Follow-up Score  (SD) 
Control Group (n=188) 42.9   (20.8) 36.2   (18.6) 
Brief Intervention (n=205) 41.4   (19.4) 31.6   (18.1) 
 
All participants allocated to the low scoring group (ie. scoring between 4 and 15) were 
included in the analysis, regardless of the substance targeted in the intervention (n = 
235).  Assumptions of normality, homogeneity of variance and sphericity were met.  
Two-way repeated measures ANOVA results showed that there was a significant 
reduction over time (F(1,233) = 14.4, p<0.001) regardless of group.  However, a 
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significant interaction effect was not observed, and the low-scoring group receiving the 
Brief Intervention at baseline did not have significantly lower mean Total Illicit 
Substance Involvement scores at follow-up compared with the Control group (Table 31, 
F(1,233) = 3.0, p=0.09).   
 
Table 31.  Total Illicit Substance Involvement Scores for low scoring participants– 
BI and Control at Baseline and Follow-up (N=235) – Pooled data. 
 Baseline Score  (SD) Follow-up Score  (SD) 
Control Group (n=118) 27.4   (14.6) 25.9   (14.7) 
Brief Intervention (n=117) 28.3   (15.1) 24.3   (14.7) 
 
Chi-squared comparisons between low and high scorers at follow-up showed that high 
scoring participants receiving a BI for any substance were significantly more likely to 
have attempted to reduce their substance use compared with low scoring BI 
participants (67.9% vs. 32.1%, Chi-squared = 13.4, p<0.001).  However an Independent 
t-test showed that there was no significant difference between high and low-scoring 
participants in terms of their rating of how much they had reduced their substance use 
(3.4 vs. 3.5, t=0.4, p=0.7). 
 
3.2.7.2 Cannabis Specific Substance Involvement 
All participants allocated to the high scoring cannabis group (ie. scoring between 16 
and 26) were included in the analysis (n = 204).  Assumptions of normality, 
homogeneity of variance and sphericity were met.  Two-way repeated measures 
ANOVA results showed that there was a significant reduction over time (F(1,202) = 
58.4, p<0.001) regardless of group.  Moreover, there was a significant interaction effect 
and the group receiving the Brief Intervention at baseline had significantly lower mean 
Cannabis Specific Substance Involvement scores at follow-up compared with the 
Control group (Table 32, F(1,202) = 4.8, p<0.05).   
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Table 32.  Cannabis Specific Substance Involvement Scores for high scoring 
participants– BI and Control at Baseline and Follow-up (N=395) – 
Pooled data. 
 Baseline Score  (SD) Follow-up Score  (SD) 
Control Group (n=96) 22.1   (3.5) 19.3   (7.0) 
Brief Intervention (n=108) 22.1   (3.5) 17.0   (8.2) 
 
All participants allocated to the low scoring group (ie. scoring between 4 and 15) were 
included in the analysis (n = 124).  Assumptions of normality, homogeneity of variance 
and sphericity were met.  Two-way repeated measures ANOVA results showed that 
there was not a significant reduction over time (F(1,122) = 3.5, p=0.07) regardless of 
group.  Additionally, a significant interaction effect was not observed, and the low-
scoring group receiving the Brief Intervention at baseline did not have significantly 
lower mean Cannabis Specific Substance Involvement scores at follow-up compared 
with the Control group (Table 33, F(1,122) = 0.4, p=0.5).   
 
Table 33.  Cannabis Specific Substance Involvement Scores for low scoring 
participants– BI and Control at Baseline and Follow-up (N=124) – 
Pooled data. 
 Baseline Score  (SD) Follow-up Score  (SD) 
Control Group (n=56) 10.4   (3.9) 9.6   (5.9) 
Brief Intervention (n=68) 10.3   (4.8) 8.8   (8.0) 
 
 
3.2.7.3 Stimulant Specific Substance Involvement 
All participants allocated to the high scoring stimulant group (ie. scoring between 16 
and 26 for cocaine or ATS) (n = 121).  Assumptions of normality, homogeneity of 
variance and sphericity were met.  Two-way repeated measures ANOVA results showed 
that there was a significant reduction over time (F(1,119) = 80.4, p<0.001) regardless of 
group.  However, the interaction effect was less strong and the group receiving the 
Brief Intervention at baseline did not have significantly lower mean Stimulant Specific 
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Substance Involvement scores at follow-up compared with the Control group (Table 34, 
F(1,119) = 3.0, p=0.09, power = 40%).   
 
Table 34.  Stimulant Specific Substance Involvement Scores (cocaine and ATS) for 
high scoring participants– BI and Control at Baseline and Follow-up 
(N=121) – Pooled data. 
 Baseline Score  (SD) Follow-up Score  (SD) 
Control Group (n=59) 21.7   (4.3) 16.1   (9.2) 
Brief Intervention (n=62) 22.8   (4.7) 14.5   (9.5) 
 
All participants allocated to the low scoring group (ie. scoring between 4 and 15 for 
cocaine or ATS) were included in the analysis (n = 108).  Assumptions of normality, 
homogeneity of variance and sphericity were met.  Two-way repeated measures 
ANOVA results showed that there was a significant reduction over time (F(1,106) = 
24.9, p<0.001) regardless of group.  Moreover, there was a significant interaction effect 
and the group receiving the Brief Intervention at baseline had significantly lower mean 
Stimulant Specific Substance Involvement scores at follow-up compared with the 
Control group (Table 35, F(1,106) = 8.5, p<0.005, power = 82%).   
 
Table 35.  Stimulant Specific Substance Involvement Scores (cocaine and ATS) for 
low scoring participants– BI and Control at Baseline and Follow-up 
(N=108) – Pooled data. 
 Baseline Score  (SD) Follow-up Score  (SD) 
Control Group (n=60) 9.1   (3.1) 8.2   (5.8) 
Brief Intervention (n=48) 10.3   (3.0) 6.8   (4.5) 
 
3.3 Participant Feedback – quantitative analysis 
 
3.3.1 Did you attempt to cut down on your drug use (after receiving the BI)? 
A total of 317 participants provided information on the above question, and of those a 
total of 262 (82.6%) reported attempting to cut down on their substance use after 
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receiving the information and feedback as part of the brief intervention (Australia 72%; 
Brazil 82.7%; India 97.4%; USA 79.5%). 
 
3.3.2 Rating of extent of reduction in drug use 
Participants receiving the BI were asked to rate out of 5 (1 being not at all, 5 being 
completely stopped) the extent to which they had reduced their substance use.  Of the 
315 responses, an average rating of 3.4 (sd=1.3) was given.  There was a small but 
significant difference between countries with regards to this rating (F(3,270) = 2.8, 
p=0.04) with Brazilian participants reporting the highest rating (3.7, sd=1.3) and 
Australian participants the lowest (3.2, sd=1.0). 
 
3.3.3 How long in weeks did the reduction in drug use last? 
Of the participants who did manage to reduce their substance use (n=224, 60.2%) the 
average time participants maintained this reduction was 11.2 weeks.  The maximum 
length of time was 49 weeks, and the minimum was 1 week (sd = 5.4 weeks, median = 
12 weeks).  While there were differences in this length of time between countries, it did 
not quite reach statistical significance (F(3,224) = 2.5, p=0.06).   
 
3.3.4 Rating of influence on general health 
Participants receiving the BI were asked to rate out of 5 (1 being no influence, 5 being 
completely influenced) the extent to which receiving the information and feedback had 
impacted on their general health.  Of the 315 responses, an average rating of 3.1 
(sd=1.3) was given.  There was a significant difference between countries with regards 
to this rating (F(3,311) = 12.1, p<0.001) with Indian participants reporting the highest 
rating (3.6, sd=1.2) and Australian participants the lowest (2.5, sd=1.1). 
 
WHO ASSIST Phase III Technical Report  
 68 
4. DISCUSSION 
 
The recruitment sample for this randomized controlled trial was likely to be employed, 
in their early thirties and residing in stable accommodation.  Sixty per cent of the 
sample identified as Caucasian which reflected the main race of two of the four 
countries from which the samples were recruited.  There were some expected profile 
differences between the countries (for example marital status, age, race, education and 
religion) however, these were considered to be a reflection of the culture from which the 
samples were drawn, or a reflection of the type of primary health care clinics from 
which they were drawn.  Similarly, there were differences in the frequency and type of 
substances used by the participants of each country, with the exception of alcohol and 
tobacco which were readily used by the majority of participants in all countries.  These 
differences impacted on the ability of each country to recruit specific drug users to the 
study.  Accordingly the majority of opioid users were recruited from India, the majority 
of ATS users were recruited from Australia, and Brazil and the USA recruited the 
majority of cocaine users.  No country had difficulty recruiting cannabis users, but it is 
worth noting that cannabis recruitment was greater in those countries where it was 
difficult to recruit other kinds of drug users.  Accordingly a larger number of cannabis 
users were recruited to the study (n=395) compared to those using ATS (n=155), 
cocaine (n=92) or opioids (n=89) despite the initial intention of the study having equity 
in recruitment numbers across drug types. 
 
There were differences between the countries with regards to the Total Illicit Substance 
Involvement Score at baseline, and Australia and the USA tended to have higher scores 
than Brazil and India.  This could reflect more frequent drug use in these countries, but 
may also be indicative of the availability of more substance types in these countries and 
a tendency towards higher levels of polydrug use.  However, there were no significant 
differences between control and BI subjects in terms of their Total Illicit Substance 
Involvement Scores, or any of their Specific Substance Involvement Scores, or the 
percentage of those who had used drugs intravenously. 
 
Fifteen per cent of the total sample had previously received some kind of treatment for 
drug and alcohol issues, generally counselling, although this tended to be some years 
in the past.  Moreover, just over three per cent of participants had injected substances 
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in the last three months, and these features, alongside the overall demographic profile 
of the sample, suggest that the participants in this study were not dependent or high 
risk substance users.  Furthermore, the high overall follow-up rate (86%) also indicates 
that this was a relatively stable sample. 
 
The inferential analysis of the pooled data (i.e. all countries’ data combined) 
demonstrated that follow-up scores were significantly lower than baseline scores for 
Total Illicit Substance Involvement, Cannabis Specific Substance Involvement, 
Stimulant Specific Substance Involvement and Opioid Specific Substance Involvement.  
This analysis did not differentiate between Control and BI groups and indicates that 
there was an overall decrease in substance use and risk over time.  However, when 
group type was taken into consideration, (i.e. Control or BI) participants receiving the 
brief intervention had significantly reduced scores for all measures (excluding Opioid 
Specific Substance Involvement) compared with Control participants.  These findings 
indicate that the brief intervention was effective compared with no intervention in 
getting participants to reduce their substance use and risk, as determined by the 
ASSIST questionnaire.  However, it also indicates that even when a brief intervention 
was not received (as in the case of Control participants at baseline) a reduction in 
ASSIST scores also was observed, albeit not to the same degree as the BI participants.  
This may suggest a “regression towards the mean” effect whereby participants 
spontaneously reduced their substance use toward the mean use of the general 
population, however, may also indicate that administration of the ASSIST questionnaire 
alone influenced participants to reduce their substance use.  The data collected by this 
study does not allow for further scrutiny of this phenomenon. 
 
While a significant interaction effect was not observed for the Opioid Specific 
Substance Involvement Score with the pooled data, there certainly was a tendency for 
participants receiving the opioid-targeted BI to have lower scores at follow-up compared 
with the Control participants, and probability tended towards significance (p=0.07).  It is 
likely that the lack of actual significance reflected the small sample size for this 
calculation (n=73), however, when Indian participants - who comprised the majority of 
opioid users - were considered on their own, there was a significant interaction effect 
(p<0.05).  This suggests that there may have been a small confounding effect when 
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data from the other countries (Australia and USA) was included in the overall pooled 
analysis, albeit considering their small sample sizes (Australia, n=2; USA, n=16). 
 
From the probability values obtained from the analysis of the pooled data, it appears 
that the BI targeting stimulants (ATS and cocaine) was the most effective statistically 
(p<0.005) followed by the BI for cannabis (p<0.05), then opioids (p=0.07).  However, 
statistical significance may not necessarily dictate the level of clinical effectiveness, 
and could reflect differences in the patterns of use of these drugs by participants.  Both 
cannabis and opioids were more likely to be daily/almost daily if used in the last three 
months compared with stimulants which were most likely to be used monthly or less by 
participants.  More frequent drug use may be associated with entrenched behaviour and 
less susceptibility to change.  However, this assumption is based on a comparison of 
the pooled data from all countries, and country by country comparisons reveal 
differences in interaction effects for each of the drugs targeted, as discussed below. 
 
With the exception of the USA site, all countries demonstrated that the BI participants 
had significantly lower Total Illicit Substance Involvement scores at follow-up compared 
with the Control subjects.  This difference appeared to be greatest among Australian 
participants.  The USA site tended towards an interaction effect (p=0.11) and while both 
groups (control and BI) had reduced scores at follow-up, the direction favoured Control 
participants having a larger decrease in scores over time than participants receiving the 
BI.  A similar pattern, including the lack of a brief intervention effect, also was observed 
for Cannabis and Stimulant Specific Substance Involvement Scores in participants 
recruited in the USA, but the pattern was unable to be determined for opioids due to the 
inadequate sample size.  Conversely, Indian and Brazilian sites demonstrated a very 
strong brief intervention effect for Cannabis Specific Substance Involvement Scores 
(p<0.005), as did Australia (p<0.005) and Brazil (p<0.01) for Stimulant Specific 
Substance Involvement Scores.  And while a significant brief intervention, or 
interaction, effect was not demonstrated in Australian participants for the Cannabis 
Specific Substance Involvement Score, the direction certainly tended towards a brief 
intervention interaction effect and it is likely that the lack of actual significance (p=0.14) 
reflected the small sample size for this calculation (n=30). 
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The reasons underlying the contrast between the Australian, Brazilian and Indian sites 
and the USA site with regards to a brief intervention effect is not completely clear.  
Within the USA site the randomization was successful in balancing the experimental 
and control groups on key variables, and the follow-up rate was adequate for clinical 
studies of this kind, with no apparent bias introduced by either the randomization or 
differential attrition at follow-up.  However, there were some protocol and participant 
differences between the USA and other sites which may have contributed to the lack of 
a brief intervention effect.   
 
One issue at the USA Connecticut site that may have affected the intervention was the 
introduction of a new ethics/IRB protocol early on in the study in which the attainment 
of informed consent comprised a lengthy and detailed process lasting 10-15 minutes.  
Prior to the induction of this new protocol, and in the other participating countries, the 
informed consent process took less than a few minutes to administer.  This extra 10-15 
minutes spent with USA participants may have either diluted the effect of the BI or 
served as a BI to the control group.  The findings in California which appear to be 
similar to the Connecticut findings, albeit on a smaller scale (n=33 compared with 
n=136), may have been affected in a similar way.  The IRB required that all potential 
participants provide informed consent before the initial screening, as well as providing 
informed consent for study participation.  Obtaining consent on the two occasions put 
the time spent obtaining consent from the participants well within the 10 to 15 minute 
time period found in Connecticut.  Comments made by control participants in California 
were consistent with the consent and testing procedures serving as a BI for the control 
group. 
 
A second issue was the time taken to follow-up participants at the USA site.  While the 
mean and median times were not dissimilar between sites (i.e. between 3 and 4 
months), the standard deviation and range indicate high variability, and follow-up 
ranged from as little as one month after baseline (32 days), to over one year after the 
baseline interview (435 days).  For some participants this may have impacted on the 
time available for the brief intervention to work, or have captured a period of time many 
months later where the effects of the brief intervention may have been eroded.  It is 
worth noting however, that even when outliers were removed from statistical 
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calculations of effectiveness that this difference between the USA and other sites still 
remained. 
 
A third difference in protocol that may have impacted on the effectiveness of the brief 
intervention concerned interviewer protocol.  The Australian, Brazilian and Indian sites 
tended to use the same interviewer for both the baseline and follow-up interviews for 
any one participant.  The USA used this method for around half of their participants, 
however the reminder of participants were interviewed by a different interviewer at 
baseline and follow-up, although there is no obvious reason how this would account for 
the difference between the USA and other sites.   
 
Furthermore, another point that arose during conversations with the clinical research 
staff at the USA site was the possibility that some participants may have minimized 
their alcohol and drug use at baseline, but reported more honestly at follow-up.   
It is not possible to investigate this further with the data available, and any further 
investigation would need to show that the BI group were more likely to behave in this 
was than the Control group.  
 
Finally, participants from the USA site were more likely to have received previous 
treatment for drug or alcohol issues in the past (around 30%) than participants from the 
other sites, and it is possible that on some level this modified the sensitivity of 
participants with respect to talking about their substance use within the context of the 
ASSIST questionnaire and of receiving a brief intervention.  However, it is worth noting 
that prior treatment did not appear to have an impact on the outcome in other sites.  For 
example, a brief intervention focussed on Cannabis in Brazil where 18% of participants 
had received prior drug and alcohol treatment, worked equally as well as it did in India 
where none of the participants reported receiving prior drug and alcohol treatment. 
 
The use of illicit substances often occurs within a context of other substance use.  
Moreover, there is evidence that reduction in one illicit substance such as heroin, can 
result in substitution and or increased use of another substance (Fairbank et al., 1993; 
Topp et al., 2003), and this phenomenon also has been observed within clinical 
settings.  Results from this study demonstrate that the reduction in illicit drug use due 
to the implementation of the ASSIST and linked BI does not appear to have resulted in 
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increased use of other substances including tobacco, alcohol, inhalants, sedatives or 
hallucinogens.  For all of these substances there was a significant time effect in which 
follow-up scores were significantly lower than baseline scores, regardless of group, and 
once again this may indicate regression toward the mean or an ASSIST questionnaire 
administration effect. 
 
A final aim within the quantitative analysis section of this study was to determine 
whether higher-scoring participants were impacted by the brief intervention any 
differently than were lower scoring participants.  Higher-scoring participants did show a 
significant interaction effect with regards to their Total Illicit Substance Involvement 
scores, in comparison with lower-scoring participants who only tended towards 
significance (p=0.09).  Moreover, significantly more of the higher-scoring participants 
reported attempting to decrease their drug use compared with the lower-scoring 
participants, although there was no significant difference between the two groups with 
respect to the rating of their reduction.  However, these findings were not consistent 
across substances, and while high-scorers did better than low-scorers with respect to 
Cannabis Specific Involvement scores, the opposite was true for Stimulant Specific 
Involvement scores.  While these findings may reveal some differences in susceptibility 
to a brief intervention by drug type and score, it is worth noting that the sample sizes 
from which these conclusions are drawn are somewhat limited and further investigation 
may be required. 
 
Overall it appears that the ASSIST-linked brief intervention was effective in getting 
participants to reduce their substance use and risk as measured by their ASSIST score.  
These findings were commensurate with participant feedback which was gathered at 
the 3 month follow-up interview and Section 5 in this technical report details the 
findings of the qualitative participant feedback to attempt to illuminate how this change 
actually occurred.  Over eighty per cent of all participants who received the brief 
intervention at baseline reported attempting to cut down on their substance use as a 
result of the feedback and information they had received.  Despite the differences 
between the USA and other sites with respect to the inferential analysis described 
above, almost eighty per cent of the USA participants who received the brief 
intervention also reported attempting to cut down.  While it is not possible to make a 
direct comparison with USA participants who were randomized to the control group, it 
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does suggest that the treatment that USA participants received was effective in 
facilitating an attempt to reduce substance use. 
 
4.1 Conclusion: Implications for a Public Health Approach 
 
Early intervention for substance misuse and related disorders has gained momentum 
internationally with the validation of alcohol and tobacco screening tests, and the 
development of an impressive evidence base for the efficacy of brief interventions for 
hazardous drinking and nicotine dependence.  The WHO project described in this report 
has built upon this research to support an early intervention approach for illicit drug 
use.  Although the findings from a single study do not constitute sufficient reason to 
disseminate drug screening and brief intervention strategies internationally, this study 
does have important implications for the initiation of demonstration programmes in the 
context of a public health approach to early intervention in general medical settings.   
 
There are a variety of reasons why a public health approach to the early identification 
of illicit drug use is warranted in health care and social service settings.   
 
The availability of new validated screening tests, such as the WHO ASSIST, which 
provide the basis for an integrated approach to substance misuse across alcohol, 
tobacco and eight other psychoactive substances (Humeniuk et al., in press).  
Scientific studies that brief interventions, brief treatments, and traditional treatments for 
cannabis (and other substance) use disorders are effective (Babor et al., 2006).  
The compelling needs of medical and public health practitioners in both developing and 
developed countries for a comprehensive approach to HIV infection and other 
conditions related to substance misuse. 
The economies of scale associated with multiple risk factor screening and intervention 
for co-occurring conditions such as risky alcohol use, cigarette smoking and illicit drug 
use. 
 
To the extent that brief interventions for illicit drug use can be formulated in the context 
of a public health approach directed at high risk populations, we believe that strong 
consideration should be given to translating into clinical practice the kinds of 
programmes studied in the WHO ASSIST Project.   
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Translation from research to practice can be considered at two levels: 1) making 
scientific knowledge accessible and relevant to practitioners; and 2) improving the 
health of the population by broad dissemination of effective health promotion and 
secondary prevention technologies.  Based on the results of this project, the following 
recommendations seem warranted: 
 
Broad dissemination by WHO of the ASSIST screening and brief intervention manuals, 
which should proceed under the guidance of an international Advisory group that can 
monitor utilization and oversee further developments in the instrument and clinical 
procedures. 
Establishment of training and reference centres that are capable of providing 
workshops and consultation on the applications of the ASSIST materials in different 
parts of the world. 
Planning and monitoring of large-scale demonstration programmes that attempt to 
integrate the ASSIST technologies into the routine work of health care delivery 
systems. 
Further research focusing on ASSIST training, programme implementation and cost 
effectiveness should be encouraged at both the national and international levels.   
 
There is general agreement on the need to “broaden the base” of drug treatment by 
expanding services to less severe cases and populations at risk.  In order for this to 
happen, the traditional, specialized care model of substance abuse treatment will have 
to be expanded to include a new population-based healthcare management perspective 
in which persons experiencing or at risk of substance use disorders are provided with a 
range of early intervention services, including screening, brief intervention, and brief 
treatment.  These services should be designed to fit the needs of defined populations, 
with different providers, such as nurses and community health workers, appropriately 
trained, supervised and supported so that they can integrate ASSIST technologies and 
procedures into routine practice.  Alternative implementation models for screening, brief 
intervention, and referral should be considered where there are limited resources or 
staff resistance, such as using interns from professional programmes that train 
physicians, nurses, psychologists and social workers.  In all cases, it is important to fit 
the ASSIST programme to the population.  It is clear from the findings of this project 
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that population-wide measures to implement the various ASSIST components have the 
potential to reduce the burden of illness associated with substance use disorders. 
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5. RESULTS – ANALYSIS AND DISCUSSION OF FEEDBACK ON BI 
 
5.1 Overview of Process and Analysis  
The ASSIST Brief Intervention Process Rating form (see APPENDIX 4) was 
administered at the follow-up interview to a total of 372 participants (Australia n = 86; 
Brazil n = 94; India n = 89; USA n = 103).  This rating form gave participants the 
opportunity to provide feedback about the ASSIST-linked brief intervention via semi-
structured questionnaire consisting of a series of open-ended questions and rating 
scales.  Prior to the administration of the questionnaire participants were reminded that 
during their baseline interview the interviewer had given them feedback and information 
on their substance use, and had discussed with them some of the positive and negative 
aspects of their substance use.  Participants were informed that the aim of this semi-
structured questionnaire was to find out what they honestly thought of the feedback and 
information they received in general; which specific aspects of the session (if any) 
changed their substance use behaviour, and whether the Substance Users Guide 
(Humeniuk et al., 2003) that was provided at the end of their session was useful.  The 
results of three parts of the questionnaire are presented below.  
 
The aim of the analyses of participants’ comments was to elucidate client perspectives 
about which aspects of the ASSIST-linked BI were most helpful in mediating change 
from the perspective of the participant. 
 
Participant responses were recorded on the questionnaire by the interviewer.  
Responses for each question were considered to be a data set and each response 
within that data set was allocated an individual identification number; the question 
number followed by individual identification number is shown in brackets at the end of 
each respective response.  Where necessary [square brackets] surround words inserted 
for purposes of clarity.  Responses to each open-ended question were coded using 
thematic analysis (Braun & Clarke, 2006).  Responses in each data set were examined 
for similarities and/or differences, and themes were identified and coded manually.  The 
analyses of several themes identified are presented below and where applicable, these 
themes are discussed in conjunction with results from participants’ rating scales.  The 
analyses identified several broad themes from the content of the comments made by 
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participants.  It is important to note that very few comments related entirely to one 
theme and the themes identified below are not necessarily mutually exclusive.  
 
5.2 Participants’ general comments on the Information and Feedback provided 
(Q9.1) 
Three hundred and eleven (83.6%) of the 372 participants who were available for follow 
up at three months commented on their understanding of the purpose of the feedback 
and information they received on substance use as part of the BI.  Eleven (3.5%) 
participants stated they did not know or could not remember.  The analysis of 
participants’ comments identified three ‘purpose’ related themes: (1) to help, (2) to 
inform, and (3) to raise awareness. Each of these themes is described below. 
 
5.2.1 ‘To Help’  
Participants frequently (n=59, 19%) referred to ways in which the feedback and 
information they had received been helpful in several ways.  For example, some 
participants directly linked the purpose of the feedback and information to ‘helping’ 
them stop:  
- Give me information about my drug use and help me to stop   (9.1: 80) 
- To help him not use (9.1:347) 
- To help her quit using marijuana (9.1:320) 
- To help people stop using (9.1:296) 
or reduce their substance use, 
- Try and help people reduce their use of drugs. Make them aware of the health 
risks (9.1:36) 
- To help me reduce my drug use (9.1:64) 
- Pamphlets helped to realize what he does to his body, helped him cut down 
(9.1:295) 
Other participants stated that they thought the purpose of the feedback and information 
provided ASSIST-linked BI was to help them understand their substance use: 
- To help us try and understand the harms associated with drug use (9.1:17) 
- Try help me to understand the harmful effects on me of using ATS (9.1: 72) 
- To help me understand risks (9.1:75) 
- To help him understand what he is doing with regards to drugs and make a better 
judgment about whether to stop or not (9.1:28) 
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Overall, the sentiments expressed under the theme of ‘help’ were couched in terms of 
the benefits gained from taking part in the study. 
- I found it good and it helped me (9.1:131) 
- Thought we helped her to boost confidence, work through set backs, useful hand 
outs (9.1:339) 
- Helpful info, to give options for cutting back/quitting. At this point and time he isn't 
ready so the info was useful but cannot replace the feeling he is receiving from 
the drugs   (9.1:348) 
 
5.2.2 ‘To Inform’  
A total of 57 (18.3%) participants referred to purpose of the feedback and information 
on drug use as a way of providing information.  Participants talked about ‘information’ 
and being ‘informed’ in a variety of ways.  For some participants the purpose of the 
session was simply a means of providing information: 
- To give people information about drugs I suppose (9.1:40) 
- To give information about drugs  (9.1:120) 
While other participants related the information provided as being purposely driven to 
inform about the harms or health risks associated with substance use: 
- For informing me that cannabis is harmful for me (9.1: 197) 
- To give information on drugs and their harm (9.1: 117) 
- For informing me that cannabis is harmful for me (9.1: 185) 
Participants frequently connected the provision of information about health risks and 
harms to the benefits of reducing or ceasing substance use: 
- Help inform, to understand why you use something and give info to help stop. Lots 
of medical info that people don't know about withdrawal is very helpful (9.1:337) 
- To make me think about cutting back my drug use/to inform me of the health risk 
of the drugs I use (9.1:20) 
- For informing me that cannabis is dangerous for my life, I should give up cannabis 
(9.1:194) 
- Informing me of long term problems and repercussions of my smoking. At the time 
it made me question my uses. I have been weak lately but will cut down (9.1:6) 
- Provide information to people and get people to stop (9.1:65) 
- For informing me that I should quit drugs (9.1:184) 
- For informing me that I should give up cannabis (9.1:192) 
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- For informing me that I should give up using cannabis, it will spoil my life 
(9.1:228) 
- For informing me that I should give my opioids (9.1:231) 
- For improvement of my life, I should give my cannabis (9.1:257) 
- Informative in case he wanted to change his habits (9.1:307) 
- Smoking so information gave me extra help to stay cut down (9.1:345) 
More than half (63.2%) of the 57 comments that referred to information came from India 
where it appears that a literal interpretation of ‘information’ was taken.   
 
5.2.3 ‘To Raise Awareness’ 
Forty nine (15.8%) of the comments that arose in this theme related to the provision of 
information and feedback to a creating a raised awareness of the harms, health effects, 
risks, consequences, problems, implications, dangers of using substances: 
- To make me aware (9.1: 13) 
- To give overall description of effects of these substances. Makes you aware of the 
health effects of using these substances (9.1: 25) 
- To make me aware of effect of drugs on self (9.1: 27) 
- Create an awareness of risks associated with use (9.1: 29) 
- To make the user more aware of harmful effects of drugs (9.1: 31) 
- To make me aware of what substances were doing - of the consequences (9.1: 
33) 
- To make me aware of problems with drug use (9.1: 46) 
- Made her aware of risks of using drugs (9.1: 49) 
- Made me aware of risks and how much I had been taking (54). 
As with the comments in the ‘To help’ theme participants made about being more 
aware were often related to reducing substance use: 
- Try and help people reduce their use of drugs. Make them aware of the health 
risks (9.1: 36). 
- To help cut down their drug use-make them aware of the harms involved in using 
a particular drug (9.1: 73). 
- To create awareness in me so that I can give up cannabis and other drugs. (9.1: 
222). 
Comments from some participants also referred to becoming more aware of their levels 
of use: 
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- To see how much I used; to make me more aware of my drug use and harms 
associated with my level of drug use (9.1:12). 
- Increase awareness and to bring to my attention what my intake was (9.1:79). 
And the effects or consequences of using: 
- To make me aware of my drug use/how it effects me and other people/work (9.1: 
69). 
- Makes me aware of risks and dangers associated and think more carefully about 
actions (9.1: 76). 
- Awareness of the consequences of drug use (9.1: 283). 
 
Comments, outlined in the three themes above were representative of the kinds of 
positive feedback received from participants about the ASSIST-linked BI process and 
its ability to raise awareness about levels of substance use and subsequent potential 
health effects of continued use.  Evidence of participants’ increased awareness of 
levels of use and possible consequences of continued use suggest that the ASSIST-
linked BI facilitated movement from pre-contemplation to contemplation (Prochaska & 
Di Clemente, 1982; Prochaska et al., 2004), although it is worth noting that this concept 
was not formally recorded.  The overall message participants conveyed about the 
purpose of the feedback and information they received is perhaps best summed up by a 
comment made by one participant who said the BI was like a “Slap in the face it woke 
me up to realise what I was doing” (40). 
 
5.3 Influence of ASSIST BI on health behaviour (Q9.2) 
Participants (N=315) were asked to rate the influence of the ASSIST-linked BI on their 
health behaviour on a five point Likert scale (rating scale: 1 = ‘no influence’, 5 = 
‘completely influenced’).  The bar chart below (see Figure 9) shows the majority of 
participants (260, 82.5%) rated the influence of the ASSIST-linked BI at two or more 
and the mean score was 3.1.  There was a significant difference between countries with 
respect to this rating with India having the highest average score (3.6) and Australia the 
lowest (2.5). 
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Figure 9. Brief Intervention group – rating of influence on health behaviour 
(Q9.2a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Comments made by participants who rated the influence of the BI at two or more (260, 
82.5%) were analysed separately from those who rated the influence at one (55, 
17.5%).   
 
5.3.1 Themes identified (Q9.2b) 
Four broad themes ‘Cutting down’, ‘Stopping use’, ‘Thinking about it’ and ‘Feeling 
better’ were identified from the analysis of comments from the 260 participants who 
stated the ASSIST BI had influenced their health behaviour (rating 2 or more).    
 
5.3.1.1 ‘Feeling Better’ 
Comments identified in this theme occurred only with participants from India (49, 
18.5%).  All participants from India expressed influence on health behaviour in terms of 
the resultant outcomes that had been achieved after they had cut down, rather than 
expressing the influence in terms of the process of reducing their substance use: 
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- I feel better (9.2c:188) 
- My health is better (9.2c:200) 
- My health is improved (9.2c:202) 
Feeling happy featured strongly and (22, 44.9%) participants mentioned feeling happy: 
- I am happy now (9.2c:255) 
- I feel energetic and happy (9.2c: 201) 
- I am healthy and happy now (9.2c: 212) 
Participants also referred to physical improvements such as a gain in appetite (10, 
20.4%), or improved sleep (7, 14.3%):  
- My health is improving and my appetite is increased (9.2c: 251) 
- I am physically better. I sleep well, eat well (9.2c:203)  
- Now I FEEL PHYSICALLY FIT. My social life is also better (9.2c:224)  
Only three of the Indian participants’ actually expressed the influence on their health 
behaviour in terms of cutting down or reducing their substance use: 
- I am feeling better now after reducing the frequency and quantity of cannabis 
(9.2c:222) 
- After reduced using the opioids (frequency & quantity). I feel better (9.2c: 230) 
- After quitting smack now I am feeling well and lead a normal good life (9.2c: 243) 
Comments made by participants from India, highlighted in the above theme, indicate 
that these participants either understood the question about the effect of the 
information and feedback on their health behaviour in a different way to participants 
from other sites, or the question was interpreted in a way that evoked responses in 
terms of outcomes, and in particular positive outcomes, rather than processes.   
 
As the above theme was unique to the Indian data set, comments from this cohort do 
not appear in the three themes that follow  
  
5.3.1.2 ‘Cutting down’ 
The most dominant theme identified from the analysis of those who rated the influence 
of the ASSIST-linked BI on their health behaviour at two or more, centred around 
issues of ‘cutting down’.  Participants mentioned they had cut down their substance use 
and many related this action to a raised awareness of the effects of substance use.  For 
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example, participants stated that the information they received provided the impetus for 
cutting down: 
- Made me aware of what I was doing to myself. Gave incentive to cut down 
(9.2c:330) 
- Realised what damage dope and ecstasy can do and cut down (9.2c:32) 
- Reminded me of effects of drugs - cut down use (9.2c:31) 
- Survey made me see how I was using drugs-made me more aware/more 
conscious of the problems associated with drug use. I did cut down my ATS use 
(9.2c:37). 
- Definitely stopped crack after talking, cut down on marijuana by weaning down 
amount then stopped, also cut down on cigs (amount) (9.2c:332) 
- When talking about cutting down, participants also referred to the booklet: 
- Read about all the drugs I used in the booklet.  Knew it already but it gave me a 
bit more info.  I cut down on pills but still smoking dope (9.2c: 47) 
- Read it and thought about it and it lasted a couple of weeks but didn't last. Cut 
down on alcohol and ATS.(9.2c: 26), 
and to specific techniques that were outlined in the take home material (Humeniuk et 
al., 2003) received at the conclusion of the ASSIST-linked brief intervention.  These 
techniques included: increasing physical activity; setting financial goals, and getting a 
check-up on their health, 
- Cut down smoking dope during the week and increased physical activity (9.2c:24) 
- Cut down ATS use. Went and got check up by Dr. Found booklet informative and 
made me aware of harms. (9.2c:55) 
- Cut down on ATS & alcohol use. Set some financial goals-trying to save money-
limited the amount of money I take with me so that I don't buy drugs/focusing in 
on my health-exercise more (9.2c:60) 
 
There were frequent comments to the influence of an increased of awareness of the 
problems and/or side effects of particular illicit substances:  
- Particular with 'e' use-made me aware of problems/side effects and I have cut 
down using (9.2c: 63) 
- Thought about side effects and risks and decided to cut down on cigarettes, 
drinking and amphetamines. Cemented what I already knew. (9.2c: 76) 
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- Cutting down on amphets and dope and become more aware of what was 
happening in that lifestyle (9.2c: 53) 
- Cut down on dope - not smoking during the day at all and cut down on amount 
smoked and frequency (9.2c: 50) 
Participants also noted the influence of friendships and social settings and the impact 
these have on substance use: 
- Made me more aware and cut down and not go out as much. Also made my 
friends aware as I spoke with them about it (62) 
- Mates hassling me and information you gave me cut down on pills (9.2c: 65) 
- Have cut down on ATS not completely and I probably will have lapses but it has 
been difficult staying away from drug-using friends. I left Adelaide to get away 
from drug using friends in part but I have cut down a significant amount  (9.2c: 80) 
 
5.3.1.3 ‘Stopping use’ 
Most participants reported that they had reduced their substance use however, there 
were a few participants who reported that receiving the information and feedback 
compelled them to stop using illicit substances completely:   
- Gave me self worth-changed my whole life. We changed our entire environment, 
cut connection with all users. Didn't go to parties and made a decision to stop 
using. My health has improved and I feel great! (9.2c:82) 
- I stopped the use of drugs, it was wonderful, I loved your talk (9.2c:163) 
- Thought I should cut down-weighed up positives & negatives. Last 8 weeks 
haven't used ATS at all (9.2c:42). 
- Stopped using and haven't since (9.2c:54) 
- Whenever I wanted to smoke I remembered what you had said, I saw it was 
serious (9.2c:143) 
- It was an encouragement to quit altogether (9.2c:154) 
- Stopped using everything completely (9.2c:34)   
The comments outlined in the two themes above focused on ‘cutting down’ and 
‘stopping’ substance use and may reflect at least some resolution in ambivalence by 
these participants.  However, in the following theme ‘I’m thinking about it’ participants’ 
comments show a continued ambivalence about drug use.  
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5.3.1.4 ‘Thinking about it’ 
Many participants reported that they were making plans to modify their illicit substance 
use in future.  For example, participants commented that the information provided 
reinforced their understanding that long term illicit substance use is untenable: 
- Hasn't influenced my behaviour so far but has reinforced my belief that smoking 
can't be a long term habit and that I must cut down. I have plans to cut down over 
the next few weeks (9.2c:6).  
- Planning to cut down and still want to but with Xmas/NY it has been difficult 
(9.2c:59). 
- Still using weekly to monthly but cut down no. of pills taking at each sitting. 
Getting to stage where I have had enough and I am thinking about giving up 
completely (9.2c:72). 
- Made me more aware of harmful consequences of smoking cannabis. 
Experiencing depression from my cannabis use. Weighed out pros and cons of 
use. Still cutting down on use (9.2c: 81.) 
 
There were clear differences in the way in which individuals took up the information and 
feedback provided as part of the ASSIST-linked BI.  Comments in the section above 
indicate that many participants were already aware of the dangers of illicit substance 
use but the process of being presented with the information again actually impacted on 
their health behaviour, making them rethink, or remember the dangers, risks associated 
with illicit substance taking.  
 
The comments grouped under the theme ‘I’m thinking about it’ are consistent with what 
would be expected from people who are ‘contemplating’ change (Prochaska & Di 
Clemente, 1982).  Although these comments indicate that these participants have not 
yet changed their pattern of substance use, many of these comments show that the BI 
influenced their thinking about the health implications of their behaviour, and as such 
they indicate a potential for change in the future.   
 
Comments chosen to illustrate the three themes above (Cutting down; Stopping use 
and Thinking about it) capture the main ideas put forward by the majority of participants 
who reported their health behaviours were influenced by the BI.  
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Many of these comments include instances of self motivated statements that can be 
seen to be markers of change– these comments indicate an engagement in the 
processes of change as highlighted by DiClemente (2007): 
“Critical change tasks include the creation of concern and interest in change 
(precontemplation), decisional considerations, and decision making (contemplations), 
commitment and implementation planning (preparation), initial modification of the 
behaviour (actions, and sustaining the new behaviour and creating a stable new pattern 
(maintenance)”.  
 
5.3.2 Themes identified (Q9.2b) 
Comments from those participants (55, 17.5%) who reported that the feedback and 
information they had received as part of the ASSIST-linked BI had no influence on their 
health behaviour (i.e., those who rated question 9.2a at one) identified four themes, 
‘Heard it all before’, ‘Choice’, ‘It’s not an issue’ and ‘I can’t give up’, each of which is 
discussed below: 
 
5.3.2.1 ‘Heard it all before’ 
These participants reported already being aware of the information and, as a result, the 
information had little or not influenced them to change their health behaviour: 
- Heard the stuff before (9.2b: 14) 
- I already knew about the effects of drugs. I read a lot (9.2b: 99) 
- I already know everything the use can cause; I have experience; this survey is 
useless for me (9.2b: 100) 
- Has heard it all before, gave info to someone else who is a heavy smoker 
(9.2b:306) 
- Already aware of dangers (9.2b:7). 
 
The comments that make up the theme ‘It’s not an issue’ can be seen to add a slightly 
different perspective to the theme outlined above.  In this theme participants intimate 
that not only have they heard it before, but it is their previous knowledge about problem 
drug behaviour that enables them to say that their own substance taking behaviour is 
not problematic.  For example, some participants reported that they were well informed 
regarding illicit substance use and they positioned their substance use as not being an 
issue for them:  
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5.3.2.2 ‘It’s not an issue’  
- As long as you are in control and it doesn't effect anyone else 'why change what 
is working for you?' (9.2b:307) 
- I don't think I read the information. I am happy with my level of using and don't 
think I'm in any danger (9.2b:20) 
- Never had problems so there was nothing to change. Legalize marijuana 
(9.2b:305) 
Sometimes the idea that illicit substance use was a ‘non issue’ was expressed as the 
result of being informed about the associated risks: 
- Choosing to smoke at the moment. I know the risks associated with it (9.2b:2).       
- I already 'knew' the info, I make my own choices (9.2b:310). 
- Class myself as well informed re drugs.  I don't believe I am in a hazardous group, 
i.e. drug use (9.2b:9.) 
- The drug information was interesting but as I don't have a problem it didn't affect 
my behaviour. Thought the manual was too general and not relevant (9.2b:19). 
The comments above convey the idea that these participants have previously engaged 
with information on substance use and their decision not to change their own substance 
taking behaviour can be seen as an active choice.   
 
5.3.2.3 ‘I can’t give up’ 
Although not as dominant as the two themes above, the comments below highlight that 
some participants felt set in their ways, and for some this feeling was expressed in 
terms of being unable to change: 
- I'm set in my ways (9.2b:15) 
- I don't know. I guess I'm set in my ways. Was trying to cut down on dope but not 
because of the information (9.2b:4) 
- Set in his ways, he enjoys marijuana (9.2b:278) 
- I don't have it in me, and don't even manage to try to improve (9.2b:94) 
- I am habituated now, no one can affect my habit (9.2b:254) 
- I am habituated now, I cannot live without cannabis.(9.2b:183) 
- I am set in my ways, not changing, marijuana should be legalized. I do like to 
learn things though.(9.2b:302) 
- I cannot give up drugs  (9.2b:215) 
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In order to explore the extent of this influence on their health behaviour participants 
were asked to indicate whether they actually reduced their substance use and, if they 
did, how long they maintained this reduction.  
 
5.4 Did you reduce your substance use? (Q9.3a and b) 
Two hundred and sixty two (82.8%) participants indicated that they did attempt to 
reduce their substance use after receiving feedback and information at baseline.  India 
reported the highest proportion of participants attempting to cut down (97%) while 
Australia reported the lowest (72%).  These participants were asked to rate the extent 
to which they reduced their substance use (1 = ‘No Reduction’; 5 = ‘Completely 
Stopped’) and the mean response was 3.4 (median = 3).  There was a small but 
significant difference between the sites with Brazil having the highest score and 
Australia the lowest.  
 
5.5 Length of time of reduction (Q9.3c) 
Of the participants who did manage to reduce their substance use (n=224, 60.2%) the 
average time participants maintained this reduction was 11.2 weeks.  The maximum 
length of time was 49 weeks, and the minimum was 1 week (sd = 5.4 weeks, median = 
12 weeks).  
 
5.6 What influenced your health behaviour? (Q9.4) 
Participants also were invited to comment on which aspects of the information and 
feedback most influenced their health behaviour (substance use).  A total of 266 
(71.5%) of participants responded to this question.   
 
There were two dominant themes identified in the analysis ‘Obligations and 
responsibilities’ and ‘Identifying and defining the problem’.  The first theme: ‘Obligations 
and responsibilities’ was identified almost exclusively in comments from participants in 
India (n= 75, 20.2%).  The second theme: Identifying and defining the problem’ centred 
around comments relating to three aspects of the information and feedback identified 
by participants as being most influential: 1) the score, 2) the interview and 3) hearing 
myself speak.  These themes are discussed separately below.   
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5.6.1 ‘Obligations and responsibilities’  
Participants’ comments in this theme expressed notions of obligations and 
responsibilities.  These issues were frequently framed in terms of the impact of 
substance use on family (59 of 62 occasions): 
- Cannabis is harmful for my health, family and future of my children (9.4:2). 
- I should avoid using cannabis for welfare of my family and my future. (9.4:4) 
- I should engage myself in family and immediately give up cannabis  (9.4:19),  
Family was also mentioned three times in the comments from participants in Brazil:  
- That health was being impaired by the use of drug and alcohol, that I could ask 
my family for help (9.4:107). 
- Health, money (I was spending a lot on the drug and disregarding home and 
family things) (9.4:145). 
- How much crack was harming the pocket, the family and the health (9.4:160). 
It was also notable that ‘family’ was not mentioned by Australian or American 
participants.  Expressions in terms of obligations were made frequently and exclusively 
by Indian and Brazilian (to a lesser degree) participants.  For example the word ‘should’ 
arose 63 times in comments from Indian participants: 
- My future is in my hand. I should immediately give up cannabis for my future and 
health  (9.4:22) 
- For improving my social, economic and physical condition, I should give up 
cannabis  (9.4:37)    
- I should involve myself in family cannabis will spoil my life. I am responsible for 
quitting cannabis (9.4:47) 
- I should involve myself in family. I can save my future be quitting drugs (9.4:47) 
 and twice in comments from Brazilian participants: 
- That I should cut down on the use (9.4:91). 
- Hints on how to stop, places and friends I should stay away from, health problems 
it could cause, (9.4:148). 
 
It is also of interest that expressions of personal responsibility for substance taking 
behaviour only arose in comments from participants in India: 
- I am responsible for avoiding cannabis, I should avoid meeting my friends (who 
use cannabis) (9.4:75) 
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- If I avoid cannabis, my family will be happy and I AM RESPONSIBLE FOR IT.  
(9.4:76) 
- I am responsible for quitting cannabis as I STARTED IT (9.4:7) 
- I am responsible for quitting cannabis as I MYSELF STARTED IT I should 
immediately quit cannabis (9.4:15) 
- I am responsible for quitting cannabis. I should involve myself in family (9.4:16) 
 
Overall, participants from India framed their answers to this question in terms of the 
general influence of the ASSIST-linked brief intervention, and their answers focussed 
on stopping substance use and the benefits that would be obtained when this was 
achieved.  
 
5.6.2 Identifying and defining ‘the problem’ 
 
5.6.2.1 ‘The problem’  
Several participants spoke specifically about the way in which receiving a ‘score’ 
highlighted the problem of illicit substance use and the influence of that on their health 
behaviour.  For example, for quite a few participants having a score made ‘it’ (their 
substance taking behaviour) more real:  
- The score for alcohol and cannabis (9.4:7) 
- The score put it into perspective, it made it more definite – more objective 
(9.4:43). 
- Seeing it on paper and the risk score (9.4:44). 
- The score on the form more than anything was pertinent to me as a number. I take 
more notice of numbers than words (9.4:42). 
- The score (54). 
- The numbers frightened me, made me think a lot   (9.4:152) 
 
Participants also commented on the way in which they were influenced by the 
information they received about the impact of illicit substance use on their health: 
- The information about health impairment caused by drugs  (9.4:129) 
- Refreshed information about marijuana use that I had learned in past, made me 
think about those things again (9.4:312) 
- Information about permanency of damage regarding ATS (9.4:32) 
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- Read pamphlets. Interesting information re side effects most useful.(9.4:38) 
- Receiving booklet information. (9.4:42) 
- Information and feedback, i.e. side effects of drugs, and the information 
book.(9.4:51) 
- Having the information and my drug use put down in front of me (9.4:70) 
- The information about adverse effects of drugs (9.4:121) 
 
Participants’ comments in relation to this question again highlighted the way in which 
the information and feedback they received had increased their awareness.  Some 
participants mentioned that taking part in the survey had made them think about or 
realise the effects of illicit substance use: 
- Doing survey helped convince him, made him think about doing something 
(9.4:286) 
- Refreshed information about marijuana use that I had learned in past, made me 
think about those things again (9.4:312) 
- Health risks, asthma, and future risks to kids made me try to cut down. (9.4:324) 
- It made me realise how much I was doing and how much it costs (9.4:333) 
- A bunch of the things, the questions made him aware (9.4:342) 
- Nothing in particular. Overall package made an impact (including self-help 
strategy booklet) (9.4:25) 
- Made me check about potential harms. Particularly of e's in SA. I received 
feedback about the drugs I was taking (9.4:30) 
- Feedback on how much I was using. Being made aware of my drug use. (9.4:37) 
- Made me realise that it wasn't a normal part of my life.(54) 
- Asking me how much I use made me realise what I'm putting my body through 
(9.4:58) 
- Risks and dangers on that pamphlet (feedback form) made me aware and opened 
my eyes up (9.4:74) 
- The whole lot made me pull my head out of the sand and cut down on pills 
(9.4:78) 
 
5.6.2.2 ‘Hearing myself speak’  
Participants’ comments identified in this theme suggest that it was during the process of 
actually verbalising answers to questions about their substance use that they came to 
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appreciate the significance of their substance taking behaviour.  The comments below 
were chosen to highlight some of the more common realizations participants mentioned 
they came to in the process of answering the BI questions and talking about their 
substance use:   
- Answering the questions made me realise how much I was using. The talk 
afterwards was also helpful and I was able to weigh up the good and bad (9.4:82) 
- I had never talked to a psychologist and liked it a lot, but it's hard to stop right 
away  (9.4:115) 
- Talking about her use (9.4:284) 
- Talking in general; after session went home and talked to mom about it (9.4:285) 
- If no talking happened the booklet was not useful (9.7:167): 
- Talking about it (9.4:292) 
- Just addressing the issue in general and talking about it (9.4:306) 
- Talking and getting literature about dealing with the stress (9.4:315) 
- Good pros & cons, opened my eyes. Helped me motivate to try even though not 
successful. You caught me when I wanted to stop so it gave me someone to talk 
to (9.4:325) 
- Just talking - he became aware of what he was doing (9.4:328) 
- Learning about emotional and physical side effects, plus the confidentiality of the 
talk, I trusted her (9.4:331) 
- First time I really talked to anyone and admitted that I used drugs and it was 
problem. Felt like she listened to me and gave me helpful literature and advice. 
Couldn't believe how drugs affected my teeth too (9.4:332) 
- Didn't treat like research, felt like real counselling. Opportunity for me to talk out 
loud about things (9.4:339) 
- Talking about my drug use put it in my thoughts.(9.4:6) 
 
The practice of providing people with the opportunity to weigh up the pros and cons of 
their behaviour in a non-confrontational manner is a key factor in motivational 
interviewing (Miller & Rollnick, 2002).  Although MI is considered a client centred 
approach, it is not applied entirely without direction and one important intention of MI is 
to ensure that it is the client who voices the arguments for change (Miller & Rollnick, 
2002).  Integral to the success of brief motivational interviewing is the ability to elicit 
‘change talk’ from participants and this is fundamentally linked to the interviewers’ 
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ability to empathise and listen reflectively (Miller & Rollnick, 2002).  These ideas have 
there foundations in social psychology, and in particular self-perception theory which 
posits that as one argues on behalf of a particular position he or she becomes more 
committed to that position: 
 
“In the language of self-perception theory, “As I hear myself talk, I learn what I believe.” 
In everyday language we can literally talk ourselves into (or out of) things (Bem, 1967, 
1972, cited in Miller, 2002, p. 21). 
 
The success of incorporating motivational interviewing techniques into the ASSIST-
linked BI is evident in the comments outlined above, which illustrate some of the ways 
in which participants’ valued the opportunity to hear themselves talk about the effects of 
their substance use more fully.  These comments also indicate that the opportunity to 
generate such ‘change-talk’ played an integral role in positively influencing their health 
behaviour.  As one participant put it, they were influenced by thinking, and thinking 
objectively about drug use, rather than rationalizing your use to your self (61).  
Moreover, research suggests that people who generate self-motivated behaviour for 
change are more likely and more willing to maintain that change (Deci & Ryan, 1985; 
Ryan, 1995). 
 
5.7 Analysis and discussion of feedback on ‘Self-help’ material (Q9.5) 
At completion of the BI at baseline participants (n = 372) were given a self-help booklet 
containing material designed to reinforce information discussed during the brief 
intervention (Humeniuk et al., 2003).  At the three month follow-up each participant was 
asked whether they recalled receiving the booklet, how much of it they read, and how 
useful they found it.  Analysis and discussion of participant responses to these 
questions is presented below.  
 
5.7.1 How much of the ‘Self-help’ booklet did you read? (Q9.5a) 
Each of the 242 participants (64.8%) who responded ‘yes’ to receiving the self-help 
strategies booklet at baseline were asked to rate how much of it they had read (1 = 
none, and 5 = read all).  One hundred and ninety nine participants (82.2%) reported 
reading some of the book (rating 1.5 or more) and of those 85 (35.1%) reported having 
read it all (rating 5).   
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There were differences between countries in the median rating of how much of the 
booklet had been read: Australia = 2.75, Brazil = 3.0, India = 5.0, USA =3.0.  
 
Those participants who reported having read little or none (rated ‘2’ or less) of the self-
help booklet were asked “what stopped you from reading through all of the booklet?” 
(82, 33.9%). Only one participant in the Indian cohort reported not reading the booklet, 
and the reason given was illiteracy.  Four other participants mentioned that the reason 
they did not read the booklet was because they do not like to read.  However, the most 
common response (53, 64.6%) given for not reading the booklet related to lack of time 
or interest:  
 
- Went in my glove box and I just forgot about it (9.5c:4) 
- Lack of interest/time  (9.5c:11) 
- No time to read it (9.5c:23) 
- Partly did not have time, couldn't be bothered, didn't want to hear what it was 
telling me, sort of know some of it already (9.5c:33) 
- Couldn't be bothered-time issue (9.5c:40) 
 
There were a few participants (12, 14.6%) who commented that they did not need the 
booklet because they already knew the information or it was not relevant to them: 
- Not relevant to me (9.5c:10) 
- Felt like I did not need the information (9.5c:20) 
- Did not need strategies because already intended to stop (9.5c:34) 
- Wasn't that concerned with my usage of ATS or BZD (9.5c:41) 
- Felt like she knew most of it already and didn't need it  (9.5c:54) 
 
Confidentially was an issue for one participant who mentioned that they did not take the 
booklet because they were afraid of parents seeing information: 
- Taking it home and parents seeing (9.5c:45) 
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5.7.2 How useful did you find the booklet for…? (Q9.6) 
Those participants who indicated that they had read some or all the self-help booklet 
(rating 2 or more) were asked to rate the usefulness of this material (193, 75.8%).  Five 
areas of ‘usefulness’ were explored: 
1. helping them understand their level of risk;  
2. weighing up the positive and negatives of using (drug); 
3. understanding options concerning changing their drug use;  
4. providing realistic strategies and guidelines for change, and 
5. whether it actually helped them cut down or stop using. 
 
Four responses were available for the five areas of usefulness (‘Not at all useful’, 
‘Somewhat useful’, ‘Very useful’ or ‘Don’t know’).  The majority of participants found the 
information in the self-booklet useful (combining the middle categories ‘somewhat 
useful’ and ‘very useful’) for understanding their level of risk, weighing up their drug 
use, and understanding options about changing drug use.  Providing realistic strategies 
and guidelines and helping cut down on drug use were also rated positively, but less so 
than the previous three categories (see Table 36 below).  
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Table 36 How useful was the booklet for …? n(%) 
How useful was the booklet? Not at all 
useful 
Somewhat 
useful 
Very 
useful 
Don't 
know 
Total 
N (%) 
Understanding level of risk? 8 (4.4) 54 (29.5) 109 
(59.6) 
12 (6.6) 183 (100) 
Weighing up your drug use?  14 (7.7) 58 (31.7) 103 
(56.3) 
8 (4.1) 183 (100) 
Understanding your options 
about changing drug use? 
18 (10.0) 70 (38.9) 82 (45.6) 10 (5.6) 180 (100) 
Providing realistic strategies & 
guidelines? 
21 (11.6) 75 (41.4) 74 (40.9) 11 (6.1) 181 (100) 
Helping you cut down on use? 33 (18.1) 59 (32.4) 84 (46.2) 6 (3.3) 182 (100) 
 
 
5.8 Participants’ final comments 
 
At the conclusion of the follow-up interview, participants were asked whether there was 
anything else they would like to say about their participation in this project and a total 
of 164 (44.1%) participants took the opportunity to comment:  Australia (56, 65.1%); 
Brazil (43, 45.7%); India (5, 5.6%); and USA (60, 58.2%).  Analysis revealed the 
majority of comments were positive with participants frequently expressing, in a variety 
of ways, the benefits they gained from taking part in the study.  Many of these 
comments echoed the positive statements made earlier in the interview.  For example, 
several participants stated that the ASSIST-linked BI was a ‘good program’ and that it 
had made them think about their substance use: 
- Good to have the personal feedback-makes it more meaningful (9.7:37) 
- Liked a lot because there was feedback and referral to help him, thanked a lot 
(9.7: 94) 
- Not really-I was thinking about cutting down & your info just cemented this. The 
interview was good-the info useful-self help book really helped me (9.7:73) 
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- Just what I needed-came at right time. Have since thought about the baseline 
interview at least once a week  (9.7:83) 
- I don't like to read anything, so the interview was more interesting     (9.7:165) 
- No, except that interviewer is a good coach, can't talk about this with other people 
(9.7:335) 
 
Several participants took the opportunity to make comment about the project itself and 
provide feedback about issues that were not able to be raised previously.  For example, 
while participants talked about the benefits of having the opportunity to talk about their 
substance use, they also raised the issue of confidentiality, which is of particular 
importance when dealing with illicit substance use.  While the specifics of confidentiality 
issues varied, the general message participants gave was one of having been unable to 
talk about their substance use with others because they did not feel safe.   
- Afraid to talk to doctors b/c not surgery candidate for surgery, back pain (9.7:289) 
- First time I ever talked to anyone about marijuana besides my grandmother or 
smoking friends (9.7:293) 
- Very good because when you hide it even though you know you have problems 
and talk about it, it feels good for a change. I was in fear of the habit, afraid of 
drugs I used   (9.7:332) 
- No, except that interviewer is a good coach, can't talk about this with other people 
(9.7:335) 
- Common sense, easy to talk to, he likes it because confidential (9.7:333) 
- One on one session good. Comfortable & easygoing session. Very discreet. Not 
too long. (9.7:77) 
- Glad this doesn't go in medical record, bad for insurance (9.7:313) 
- Like the realistic approach, people need to get this information but they need to 
feel safe when they talk about it  (9.7:331) 
- Should stay in touch with people, don't forget to check on them. Good to have 
another person to talk about marijuana with.(9.7:337) 
- Good to have someone to talk about drugs with (9.7:346) 
- Appreciate us helping him have somebody to talk to besides sister who is good 
support (9.7:345) 
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These comments identify that many illicit substances users have a need to talk 
confidentially about their substance use.  These comments also indicate that the 
ASSIST-linked BI was able to meet that need. 
 
Others comments drew attention to participants’ need to make contact and talk about 
their substance use, and several participants raised the issue of keeping in touch or 
having more sessions: 
 
- It was very good and I'd like to talk to you more times, if it's possible  (9.7:115) 
- There could be more meetings to help reduce or quit the use, more sessions 
(9.7:162) 
- That booklet and information packet was really helpful. Maybe you could add 
reminders or emails about 1/2 way through, 3 months is long (9.7:323) 
- It's hard to do the exercise in the manual alone, you need follow-up of a specialist 
(9.7:142) 
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6. CONCLUDING COMMENTS 
 
The findings from the qualitative analysis above are commensurate with the inferential 
analysis of the effectiveness of the brief intervention.  While there did appear to be 
some cultural differences in interpretation of the questions and expression of how the 
brief intervention had impacted on them, participants’ comments point to the successful 
and appropriate incorporation of ASSIST scores within a motivational interviewing 
context.  The personal feedback given to participants through their ASSIST scores 
provided a non-confrontational way of drawing attention to the less positive aspects 
(risks) of continued substance use in ways that elicit the person’s own reasons for and 
advantages of change.  The overall results of this study show that participants allocated 
to the Brief Intervention Group did change their substance taking behaviour when 
compared to the Control group.  While stage of change was not formally recorded these 
findings do suggest that the implementation of the ASSIST-linked BI facilitated 
participants’ ‘readiness to change’, and the many positive comments from participants 
regarding the feedback and information provided indicate that participants responded 
well to this opportunity for change.   
 
It was interesting to note that participants from the USA provided feedback on their 
experiences which was comparable with the other sites.  That is, despite not seeing a 
statistical interaction effect, USA participants still appeared to change their behaviour 
as a result of receiving the ASSIST-linked brief intervention.  However, this conclusion 
is somewhat limited because it is not known how or why the Control participants 
changed their behaviour.  
 
Generally, participants’ comments, outlined in the analyses above, showed an 
awareness of substance taking behaviour occurs on a continuum of time (which is their 
life) and reveal participants’ understanding that this behaviour can have a past, a 
present and a future.  These comments also confirm that participants recognise that 
their substance taking behaviour is not a feature of their personality or a static 
character trait, and thus (especially for those who have not yet changed) there always 
remains the possibility of changing behaviour in the future.  The ‘not ready yet’ quality 
evidenced in many of the comments confirms that the most participants understand that 
substance taking behaviour is a non-static behaviour that is amenable to change, and 
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many of these comments did allude to the possibility of change at some future time – 
just not now.  
 
Evidence for the efficacy and successful implementation of brief interventions for illicit 
drugs within primary health care settings is limited.  Brief intervention studies reported 
in the literature most frequently target at-risk populations of alcohol users, while a small 
proportion focus on targeting illicit drug use.  Methodologies in these studies are varied 
and range from various forms of counselling and feedback, to more formal structured 
therapy (Barry et al., 2004).  This study was concerned with treatment efficacy, and the 
results demonstrate that the ASSIST-linked BI is effective in reducing illicit drug use as 
measured by ASSIST scores after a three month period within Primary Health Care 
settings across different cultures. 
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8. APPENDICES 
8.1 WHO ASSIST V3.0 Questionnaire 
8.2 WHO ASSIST Feedback Report Card 
8.3 WHO ASSIST Brief Intervention Record 
8.4 WHO ASSIST Brief Intervention Process Rating Form 
  
WHO  ASSIST V3.0   Questionnaire  
 
 
CLINICIAN ID    CLINIC  
 
PATIENT ID   DATE       
 
INTRODUCTION  (Please read to patient.  Can be adapted for local circumstances ) 
 
(Many drugs & medications can affect your health.  It is important for your health care provider to have 
accurate information about your use of various substances, in order to provide the best possible care.) 
The following questions ask about your experience of using alcohol, tobacco produces and other drugs 
across your lifetime and in the past three months.  These substances can be smoked, swallowed, snorted, 
inhaled, injected or taken in the form of pills (show drug card). 
Some of the substances listed may be prescribed by a doctor (like amphetamines, sedatives, pain 
medications).  For this interview, we will not record medications that are used as prescribed by your doctor.  
However, if you have taken such medications for reasons other than prescription, or taken them more 
frequently or at higher doses than prescribed, please let me know.  While we are also interested in knowing 
about your use of various illicit drugs, please be assured that information on such use will be treated as 
strictly confidential. 
 
NOTE: BEFORE ASKING QUESTIONS, GIVE ASSIST RESPONSE CARD TO PATIENT 
 
Question 1  
In your life, which of the following substances have you 
ever used?  (NON-MEDICAL USE ONLY) 
No Yes 
a.  Tobacco products (cigarettes, chewing tobacco, cigars, etc.) 0 3 
b.  Alcoholic beverages (beer, wine, spirits, etc.) 0 3 
c.  Cannabis (marijuana, pot, grass, hash, etc.) 0 3 
d.  Cocaine (coke, crack, etc.) 0 3 
e. Amphetamine type stimulants (speed, diet pills, ecstasy, etc.) 0 3 
f.  Inhalants (nitrous, glue, petrol, paint thinner, etc.) 0 3 
g.  Sedatives or Sleeping Pills (Valium, Serepax, Rohypnol, etc.) 0 3 
h.  Hallucinogens (LSD, acid, mushrooms, PCP, Special K, etc.) 0 3 
i.  Opioids (heroin, morphine, methadone, codeine, etc.) 0 3 
j.  Other - specify: 0 3 
 
Probe if all answers are negative: 
“Not even when you were in school?” 
If "No" to all items, stop interview. 
If "Yes" to any of these items, ask 
Question 2 for each substance ever used. 
 
  
 
Question 2 
In the past three months, how often have you used 
the substances you mentioned (FIRST DRUG, 
SECOND DRUG, ETC)? N
e
v
e
r 
O
n
c
e
 o
r 
T
w
ic
e
 
M
o
n
th
ly
 
W
e
e
k
ly
 
D
a
il
y
 o
r 
A
lm
o
s
t 
D
a
il
y
 
a.  Tobacco products (cigarettes, chewing tobacco, cigars, etc.) 0 2 3 4 6 
b.  Alcoholic beverages (beer, wine, spirits, etc.) 0 2 3 4 6 
c.  Cannabis (marijuana, pot, grass, hash, etc.) 0 2 3 4 6 
d.  Cocaine (coke, crack, etc.) 0 2 3 4 6 
e. Amphetamine type stimulants (speed, diet pills, ecstasy, etc.) 0 2 3 4 6 
f.  Inhalants (nitrous, glue, petrol, paint thinner, etc.) 0 2 3 4 6 
g.  Sedatives or Sleeping Pills (Valium, Serepax, Rohypnol, etc.) 0 2 3 4 6 
h.  Hallucinogens (LSD, acid, mushrooms, PCP, Special K, etc.) 0 2 3 4 6 
i.  Opioids (heroin, morphine, methadone, codeine, etc.) 0 2 3 4 6 
j.  Other - specify: 0 2 3 4 6 
 
 
If "Never" to all items in Question 2, skip to Question 6. 
 
If any substances in Question 2 were used in the previous three months, continue with 
Questions 3, 4 & 5 for each substance used. 
 
 
 
Question 3 
During the past three months, how often have you 
had a strong desire or urge to use (FIRST DRUG, 
SECOND DRUG, ETC)? N
e
v
e
r 
O
n
c
e
 o
r 
T
w
ic
e
 
M
o
n
th
ly
 
W
e
e
k
ly
 
D
a
il
y
 o
r 
A
lm
o
s
t 
D
a
il
y
 
a.  Tobacco products (cigarettes, chewing tobacco, cigars, etc.) 0 3 4 5 6 
b.  Alcoholic beverages (beer, wine, spirits, etc.) 0 3 4 5 6 
c.  Cannabis (marijuana, pot, grass, hash, etc.) 0 3 4 5 6 
d.  Cocaine (coke, crack, etc.) 0 3 4 5 6 
e. Amphetamine type stimulants (speed, diet pills, ecstasy, etc.) 0 3 4 5 6 
f.  Inhalants (nitrous, glue, petrol, paint thinner, etc.) 0 3 4 5 6 
g.  Sedatives or Sleeping Pills (Valium, Serepax, Rohypnol, etc.) 0 3 4 5 6 
h.  Hallucinogens (LSD, acid, mushrooms, PCP, Special K, etc.) 0 3 4 5 6 
i.  Opioids (heroin, morphine, methadone, codeine, etc.) 0 3 4 5 6 
j.  Other - specify: 0 3 4 5 6 
 
  
Question 4 
During the past three months, how often has your 
use of (FIRST DRUG, SECOND DRUG, ETC) 
led to health, social, legal or financial problems? N
e
v
e
r 
O
n
c
e
 o
r 
T
w
ic
e
 
M
o
n
th
ly
 
W
e
e
k
ly
 
D
a
il
y
 o
r 
A
lm
o
s
t 
D
a
il
y
 
a.  Tobacco products (cigarettes, chewing tobacco, cigars, etc.) 0 4 5 6 7 
b.  Alcoholic beverages (beer, wine, spirits, etc.) 0 4 5 6 7 
c.  Cannabis (marijuana, pot, grass, hash, etc.) 0 4 5 6 7 
d.  Cocaine (coke, crack, etc.) 0 4 5 6 7 
e. Amphetamine type stimulants (speed, diet pills, ecstasy, etc.) 0 4 5 6 7 
f.  Inhalants (nitrous, glue, petrol, paint thinner, etc.) 0 4 5 6 7 
g.  Sedatives or Sleeping Pills (Valium, Serepax, Rohypnol, etc.) 0 4 5 6 7 
h.  Hallucinogens (LSD, acid, mushrooms, PCP, Special K, etc.) 0 4 5 6 7 
i.  Opioids (heroin, morphine, methadone, codeine, etc.) 0 4 5 6 7 
j.  Other - specify: 0 4 5 6 7 
 
 
 
Question 5 
During the past three months, how often have you failed 
to do what was normally expected of you because of 
your use of (FIRST DRUG, SECOND DRUG, ETC)? N
e
v
e
r 
O
n
c
e
 o
r 
T
w
ic
e
 
M
o
n
th
ly
 
W
e
e
k
ly
 
D
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y
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r 
A
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o
s
t 
D
a
il
y
 
a.  Tobacco products      
b.  Alcoholic beverages (beer, wine, spirits, etc.) 0 5 6 7 8 
c.  Cannabis (marijuana, pot, grass, hash, etc.) 0 5 6 7 8 
d.  Cocaine (coke, crack, etc.) 0 5 6 7 8 
e. Amphetamine type stimulants (speed, diet pills, ecstasy, etc.) 0 5 6 7 8 
f.  Inhalants (nitrous, glue, petrol, paint thinner, etc.) 0 5 6 7 8 
g.  Sedatives or Sleeping Pills (Valium, Serepax, Rohypnol, etc.) 0 5 6 7 8 
h.  Hallucinogens (LSD, acid, mushrooms, PCP, Special K, etc.) 0 5 6 7 8 
i.  Opioids (heroin, morphine, methadone, codeine, etc.) 0 5 6 7 8 
j.  Other - specify: 0 5 6 7 8 
 
 
  
 
Ask Questions 6 & 7 for all substances ever used  (i.e. those endorsed in Question 1) 
 
Question 6 
Has a friend or relative or anyone else ever 
expressed concern about your use of 
(FIRST DRUG, SECOND DRUG, ETC.)? 
N
o
, 
N
e
v
e
r 
Y
e
s
, 
in
 
th
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 p
a
s
t 
3
 
m
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a.  Tobacco products (cigarettes, chewing tobacco, cigars, etc.) 0 6 3 
b.  Alcoholic beverages (beer, wine, spirits, etc.) 0 6 3 
c.  Cannabis (marijuana, pot, grass, hash, etc.) 0 6 3 
d.  Cocaine (coke, crack, etc.) 0 6 3 
e. Amphetamine type stimulants (speed, diet pills, ecstasy, etc.) 0 6 3 
f.  Inhalants (nitrous, glue, petrol, paint thinner, etc.) 0 6 3 
g.  Sedatives or Sleeping Pills (Valium, Serepax, Rohypnol, etc.) 0 6 3 
h.  Hallucinogens (LSD, acid, mushrooms, PCP, Special K, etc.) 0 6 3 
i.  Opioids (heroin, morphine, methadone, codeine, etc.) 0 6 3 
j.  Other – specify: 0 6 3 
 
 
 
Question 7 
Have you ever tried and failed to control, cut down or stop 
using (FIRST DRUG, SECOND DRUG, ETC.)? N
o
, 
N
e
v
e
r 
Y
e
s
, 
in
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e
 p
a
s
t 
3
 m
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a.  Tobacco products (cigarettes, chewing tobacco, cigars, etc.) 0 6 3 
b.  Alcoholic beverages (beer, wine, spirits, etc.) 0 6 3 
c.  Cannabis (marijuana, pot, grass, hash, etc.) 0 6 3 
d.  Cocaine (coke, crack, etc.) 0 6 3 
e. Amphetamine type stimulants (speed, diet pills, ecstasy, etc.) 0 6 3 
f.  Inhalants (nitrous, glue, petrol, paint thinner, etc.) 0 6 3 
g.  Sedatives or Sleeping Pills (Valium, Serepax, Rohypnol, etc.) 0 6 3 
h.  Hallucinogens (LSD, acid, mushrooms, PCP, Special K, etc.) 0 6 3 
i.  Opioids (heroin, morphine, methadone, codeine, etc.) 0 6 3 
j.  Other – specify: 0 6 3 
 
  
Question 8 
 
N
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Have you ever used any drug by injection? 
(NON-MEDICAL USE ONLY) 
0 2 1 
 
IMPORTANT NOTE: 
Patients who have injected drugs in the last 3 months should be asked about their pattern of 
injecting during this period, to determine their risk levels and the best course of intervention. 
PATTERN OF INJECTING  INTERVENTION GUIDELINES 
Once weekly or less                or 
Fewer than 3 days in a row 
 Brief Intervention including “risks 
associated with injecting” card 
    
More than once per week       or 
3 or more days in a row  
 Further assessment and more 
intensive treatment*  
 
HOW TO CALCULATE A SPECIFIC SUBSTANCE INVOLVEMENT SCORE. 
 
For each substance (labelled a. to j.) add up the scores received for questions 2 through 7 inclusive.  Do not 
include the results from either Q1 or Q8 in this score.  For example, a score for cannabis would be calculated 
as: Q2c + Q3c + Q4c + Q5c + Q6c + Q7c 
 
Note that Q5 for tobacco is not coded, and is calculated as: Q2a + Q3a + Q4a + Q6a + Q7a 
 
THE TYPE OF INTERVENTION IS DETERMINED BY THE PATIENT’S SPECIFIC SUBSTANCE INVOLVEMENT SCORE 
 
 Record specific 
substance score 
no 
intervention 
receive brief 
intervention 
more intensive 
treatment * 
a. tobacco  0 - 3 4 - 26 27+ 
b. alcohol  0 - 10 11 - 26 27+ 
c. cannabis  0 - 3 4 - 26 27+ 
d. cocaine  0 - 3 4 - 26 27+ 
e. amphetamine   0 - 3 4 - 26 27+ 
f. inhalants  0 - 3 4 - 26 27+ 
g. sedatives  0 - 3 4 - 26 27+ 
h. hallucinogens  0 - 3 4 - 26 27+ 
i. opioids  0 - 3 4 - 26 27+ 
j. other drugs  0 - 3 4 - 26 27+ 
 
NOTE: *FURTHER ASSESSMENT AND MORE INTENSIVE TREATMENT may be provided by the health professional(s) 
within your primary care setting, or, by a specialist drug and alcohol treatment service when available. 
 
WHO ASSIST  Feedback Report Card 
 
 
Name________________________________ Test Date _____________________ 
 
 
Specific Substance Involvement Scores 
 
Substance Score Risk Level 
 
a. Tobacco products  
 0-3 Low  
4-26 Moderate  
27+ High 
 
b. Alcoholic Beverages  
 0-10 Low 
11-26 Moderate 
27+ High 
 
c. Cannabis  
 0-3 Low  
4-26    Moderate  
27+ High 
 
d. Cocaine  
 0-3 Low  
4-26    Moderate  
27+ High 
 
e. Amphetamine type stimulants  
 0-3 Low  
4-26    Moderate  
27+ High 
 
f. Inhalants  
 0-3 Low  
4-26    Moderate  
27+ High 
 
g. Sedatives or Sleeping Pills  
 0-3 Low  
4-26    Moderate  
27+ High 
 
h. Hallucinogens  
 0-3 Low  
4-26    Moderate  
27+ High 
 
i. Opioids  
 0-3 Low  
4-26    Moderate  
27+ High 
 
j. Other - specify 
 0-3 Low  
4-26    Moderate  
27+ High 
 
What do your scores mean? 
Low: You are at low risk of health and other problems from your current pattern of use. 
 
Moderate: You are at risk of health and other problems from your current pattern of substance 
use. 
 
High: You are at high risk of experiencing severe problems (health, social, financial, legal, 
relationship) as a result of your current pattern of use and are likely to be dependent 
Are you concerned about your substance use? 
 
a. 
tobacco 
 
Your risk of experiencing these harms is:……… 
 
Regular tobacco smoking is associated with: 
Low     Moderate     High 
 (tick one) 
 
 Premature ageing, wrinkling of the skin 
 Respiratory infections and asthma 
 High blood pressure, diabetes 
 Respiratory infections, allergies and asthma in children of smokers 
 Miscarriage, premature labour and low birth weight babies for pregnant women 
 Kidney disease 
 Chronic obstructive airways disease 
 Heart disease, stroke, vascular disease 
 Cancers  
 
 
b.  
alcohol 
 
Your risk of experiencing these harms is:……… 
 
Regular excessive alcohol use is associated with: 
Low     Moderate     High 
 (tick one) 
 Hangovers,  aggressive and violent behaviour,  accidents and injury 
 Reduced sexual performance,  premature ageing 
 Digestive problems,  ulcers,  inflammation of the pancreas,  high blood pressure 
 Anxiety and depression,  relationship difficulties,  financial and work problems 
 Difficulty remembering things and solving problems 
 Deformities and brain damage in babies of pregnant women 
 Stroke,  permanent brain injury,  muscle and nerve damage 
 Liver disease,  pancreas disease 
 Cancers,  suicide 
 
 
c.  
cannabis 
 
Your risk of experiencing these harms is:…… 
 
Regular use of cannabis is associated with: 
Low     Moderate     High 
 (tick one) 
 Problems with attention and motivation  
 Anxiety, paranoia, panic, depression 
 Decreased memory and problem solving ability 
 High blood pressure 
 Asthma, bronchitis 
 Psychosis in those with a personal or family history of schizophrenia 
 Heart disease and chronic obstructive airways disease 
 Cancers 
 
 d.  
cocaine 
 
Your risk of experiencing these harms is:…. 
 
Regular use of cocaine is associated with: 
Low     Moderate     High 
 (tick one) 
 Difficulty sleeping,  heart racing,  headaches,  weight loss 
 Numbness,  tingling,  clammy skin, skin scratching or picking 
 Accidents and injury,  financial problems 
 Irrational thoughts 
 Mood swings - anxiety, depression, mania 
 Aggression and paranoia 
 Intense craving, stress from the lifestyle 
 Psychosis after repeated use of high doses 
 Sudden death from heart problems 
 
 
e.  
amphetamine 
type stimulants 
 
Your risk of experiencing these harms is:……. 
 
Regular use of amphetamine type stimulants is 
associated with: 
Low     Moderate     High 
 (tick one) 
 Difficulty sleeping,  loss of appetite and weight loss,  dehydration 
 jaw clenching,  headaches,  muscle pain 
 Mood swings –anxiety,  depression,  agitation,  mania,  panic,  paranoia 
 Tremors,  irregular heartbeat,  shortness of breath 
 Aggressive and violent behaviour 
 Psychosis after repeated use of high doses 
 Permanent damage to brain cells 
 Liver damage,  brain haemorrhage,  sudden death (from ecstasy) in rare situations 
 
 
f.  
inhalants 
 
Your risk of experiencing these harms is:….……. 
 
Regular use of inhalants is associated with: 
Low     Moderate     High 
 (tick one) 
 Dizziness and hallucinations,  drowsiness,  disorientation,  blurred vision 
 Flu like symptoms,  sinusitis,  nosebleeds 
 Indigestion,  stomach ulcers 
 Accidents and injury 
 Memory loss,  confusion,  depression,  aggression 
 Coordination difficulties,  slowed reactions,  hypoxia 
 Delirium,  seizures,  coma,  organ damage (heart,  lungs,  liver,  kidneys) 
 Death from heart failure 
 
g. 
sedatives 
Your risk of experiencing these harms is: 
 
Regular use of sedatives is associated with: 
Low     Moderate     High 
 (tick one) 
 Drowsiness, dizziness and confusion 
 Difficulty concentrating and remembering things 
 Nausea,  headaches,  unsteady gait 
 Sleeping problems 
 Anxiety and depression 
 Tolerance and dependence after a short period of use. 
 Severe withdrawal symptoms 
 Overdose and death if used with alcohol, opioids or other depressant drugs. 
 
 
h.  
hallucinogens 
 
Your risk of experiencing these harms is:……….. 
 
Regular use of hallucinogens is associated with: 
Low     Moderate     High 
 (tick one) 
 Hallucinations (pleasant or unpleasant) – visual, auditory, tactile, olfactory 
 Difficulty sleeping 
 Nausea and vomiting 
 Increased heart rate and blood pressure 
 Mood swings 
 Anxiety,  panic,  paranoia 
 Flash-backs 
 Increase the effects of mental illnesses such as schizophrenia 
 
 
i. 
opioids 
 
Your risk of experiencing these harms is: 
 
Regular use of opioids is associated with: 
Low     Moderate     High 
 (tick one) 
 Itching,  nausea and vomiting 
 Drowsiness, constipation,  tooth decay 
 Difficulty concentrating and remembering things 
 Emotional problems and social problems 
 Reduced sexual desire and sexual performance 
 Relationship difficulties 
 Financial and work problems, violations of law 
 Tolerance and dependence,  withdrawal symptoms 
 Overdose and death from respiratory failure 
 
 
 Version 1.  Last modified September 2003 
WHO ASSIST  BRIEF INTERVENTION RECORD 
 
Please fill in a Brief Intervention Record for each study participant (NB. This form is not 
administered to participants, but rather filled in by the interviewer concerning the BI 
session) 
 
 
INTERVIEWER ID            COUNTRY        CLINIC  
 
SUBJECT ID               
               
DATE TODAY               
 
 
Part 1 – General Information about the Brief Intervention 
• Column A should be completed for participants randomised to the Brief Intervention group 
who received their Brief Intervention at baseline. 
• Column B should be completed for participants randomised to the Wait-list Control group 
who received their Brief Intervention at follow-up. 
 
Part 2 – Detailed Information about the Brief Intervention 
• Same questions for both groups  
 
 
ANY FURTHER COMMENTS ON EITHER PART 1 OR PART 2 OF THE BRIEF INTERVENTION RECORD CAN BE MADE 
IN THE TEXT BOX BELOW. 
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PART 1.  General Information about the Brief Intervention 
 
7.1  TO WHICH GROUP HAS THE PARTICIPANT BEEN RANDOMISED? (PLEASE FILL IN ONE COLUMN ONLY) 
  
COLUMN A (Baseline BI) COLUMN B (Follow-up BI) 
  
a.  Brief Intervention group (tick)    b.  Weight List Control group (tick)    
  
7.2a  DATE BASELINE INTERVIEW 7.2b  DATE FOLLOW-UP INTERVIEW 
              
  
7.3a RECORD BASELINE ASSIST SCORES  7.3b RECORD FOLLOW-UP ASSIST SCORES  
  
(i) Cannabis   (i) Cannabis   
(ii) Cocaine   (ii) Cocaine   
(iii) Amphetamine-type stimulants   (iii) Amphetamine-type stimulants   
(iv) Opioids   (iv) Opioids   
  
7.4a Which drug is 
the focus of the BI?…………………………….. 
 7.4b Which drug is 
the focus of the BI?…………………………….. 
 
  
7.5a  START TIME OF BI AT BASELINE?  7.5b  START TIME OF BI AT FOLLOW-UP?  
  
  :    24 hour 
clock 
   :    24 hour 
clock 
 
  
7.6a  END TIME OF BI AT BASELINE?  7.6b  END TIME OF BI AT FOLLOW-UP?  
  
  :    24 hour 
clock 
   :    24 hour 
clock 
 
  
7.7a  LENGTH OF BI (MINUTES)    7.7b  LENGTH OF BI (MINUTES)    
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PART 2.  DETAILED INFORMATION ABOUT THE BRIEF INTERVENTION  
(TO BE COMPLETED IMMEDIATELY AFTER BRIEF INTERVENTION) 
    
7.8a  WHAT MATERIALS WERE GIVEN TO PARTICIPANT TO ACCOMPANY BRIEF INT.? (TICK ALL THAT APPLY) 
 
(i) Substance Users Guide to cutting down or stopping   
(ii) Specific Information Cannabis   
(iii) Specific Information Cocaine   
(iv) Specific Information Amphetamine-type stimulants   
(v) Specific Information Opioids   
(vii) Other (specify)   
(viii) Other (specify)   
(ix) Other (specify)   
 
7.9  This section is designed to rate the session engagement and expected outcome following 
the brief intervention.  Immediately after the brief intervention, please complete the 
following rating scale.  To what extent to you consider the client was: (please circle)? 
 
N
o
t 
a
t 
a
ll
 
     
A
 G
re
a
t 
d
e
a
l 
a.  Easy to talk to and co-operative during the session 
 
1 2 3 4 5 6 7 
b.  Resistant to talking about their substance use 
 
7 6 5 4 3 2 1 
c.  Appeared to have insight into the ways they use 
substances & potential or actual problems arising 
1 2 3 4 5 6 7 
d.  Committed to reducing the frequency of their 
substance use 
1 2 3 4 5 6 7 
e.  Committed to reducing the amount they consume of 
one or more substances 
1 2 3 4 5 6 7 
f.  Appeared to be confident that they could avoid future 
substance-related problems 
1 2 3 4 5 6 7 
  
 
   
7.9g.  Total score is derived through cumulation of Questions a. 
through f.  A high score indicates greater session engagement 
& greater likelihood of positive change through BI. 
7.9g.  Total score 
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WHO ASSIST  BRIEF INTERVENTION PROCESS RATING FORM - FOLLOW-UP 
 
To be administered to participants at follow-up concerning the Brief Intervention that they received 
at baseline (participants from Wait-List Control are not administered this form).  There are three 
main parts to this form: 
 
Part 1  General Information about the feedback and information 
 
Part 2  Specific questions concerning the information and feedback received during the session 
with the interviewer 
 
Part 3  Specific questions concerning the written information (Substance Users Guide) 
 
Please administer to participants at the follow-up interview AFTER you have 
administered the ASSIST 
 
INTERVIEWER ID            COUNTRY        CLINIC  
 
SUBJECT ID               
               
DATE TODAY               
 
What drug was the focus of the BI 
for this participant? (refer to 7.4a) 
  Use this information where term 
(drug) is found in this form 
 
How many weeks ago was the baseline interview for this participant? (refer to 7.2a)   
 
PLEASE READ TO PARTICIPANT 
You may remember that after you completed the questionnaire three months ago, the 
interviewer gave you feedback & information on your (insert drug name) use, & may have 
discussed with you the positive & negative aspects of your (drug) use.  The interviewer also 
may have given you some written information to take home & read.  This questionnaire aims 
to find out what you honestly thought of the feedback & information you received in general 
(Part 1), and also your thoughts on the specific aspects of the session with the interviewer 
(Part 2), and the written information that you were given to take home (Part 3). 
 
 
Part 1.  General  
 
9.1 COULD YOU PLEASE BRIEFLY DESCRIBE WHAT YOU THOUGHT WAS THE PURPOSE OF THE FEEDBACK AND 
INFORMATION YOU RECEIVED ON (DRUG) USE? 
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9.2a   ON A SCALE OF 1 TO 5, HOW DID THE INFORMATION AND FEEDBACK INFLUENCE YOUR HEALTH 
BEHAVIOUR? - where 1 equals “no influence whatsoever”, and 5 equals “completely 
changed my behaviour”  (Please circle) 
 
No Influence   Completely Influenced 
        
       
  
 
  1    2    3    4    5     
 
9.2b.  If ‘1’ was circled ask, “Why was there no influence on your behaviour?”  (If participant 
is having problems giving a full answer, you can prompt with questions like; “was there 
anything particular that you didn’t like about the session with the interviewer?” or 
“what do you think it would take to influence your health behaviour?”) 
 
 
 
 
 
 
 
 
9.2c..If ‘2’ or greater was circled ask, “If it did have some effect, how did it influence your 
health behaviour?” 
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No   Go to Part 3 (Q9.5) 
   
9.3a DID YOU ATTEMPT TO CUT DOWN ON 
YOUR (DRUG) USE AFTER RECEIVING 
THE FEEDBACK & INFORMATION? 
Yes   Go to Q9.3b 
 
9.3b   ON A SCALE OF 1 TO 5, TO WHAT EXTENT DID YOU ACTUALLY REDUCE YOUR (DRUG) USE? - where 1 
equals “did not reduce my (drug) use whatsoever”, and 5 equals “completely stopped 
(drug) use after the last interview”  (Please circle) 
 
No reduction   Completely Stopped 
        
       
  
 
  1    2    3    4    5     
 
 9.3c.  If circled ‘2’ or greater ask, “How long did this last?” 
(Code in weeks.  Remind participant of how many weeks 
it has been since their first interview as per 7.2a) 
    
 
 
Part 2.  Information and feedback session with interviewer 
 
9.4  WHAT PARTICULAR ASPECT OF THE FEEDBACK AND INFORMATION SESSION WITH THE INTERVIEWER 
WAS IT THAT INFLUENCED YOUR HEALTH BEHAVIOUR AND (DRUG) USE?  (If the participant is having 
problems giving a full answer, you can prompt with questions like; “what do you 
remember most about the session with the interviewer?” or “what struck you the most?”) 
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Part 3.  Written Information (See 7.8a for this participant) 
 
No    Go to Q9.7 
    
9.5a.  DO YOU REMEMBER RECEIVING THE BOOKLET “THE 
SUBSTANCE USERS GUIDE TO CUTTING DOWN OR 
STOPPING”? (Show participant a copy) 
Yes    Go to Q9.5b. 
 
9.5b   ON A SCALE OF 1 TO 5, HOW MUCH OF THE BOOKLET DID YOU READ? - where 1 equals “none of 
the booklet whatsoever”, & 5 equals “read all of booklet cover to cover” (Please circle) 
 
Read None   Read All 
        
       
  
 
  1    2    3    4    5     
 
9.5c. If circled ‘2’ or less ask, “What stopped you from reading through all of the booklet?” 
 
 
 
 
 
 
9.6.    If circled ‘2’ or more ask, “How useful did you find the 
booklet for…….….” (circle one number for each row) 
N
o
t 
u
s
e
fu
l 
S
o
m
e
-w
h
a
t 
u
s
e
fu
l 
V
e
ry
 u
s
e
fu
l 
D
o
n
’t
 k
n
o
w
 
a. helping you to understand your level of risk 1 2 3 9 
b. helping you to weigh up the positive & negatives of using (drug) 1 2 3 9 
c. understanding your options concerning changing your (drug) use 1 2 3 9 
d. providing you with realistic strategies & guidelines for change 1 2 3 9 
e. actually helping you to cut down or stop using (drug) 1 2 3 9 
 
9.7 IS THERE ANYTHING ELSE YOU WOULD LIKE TO TELL US ABOUT YOUR PARTICIPATION IN THIS PROJECT? 
For example, how could the feedback and information be improved? 
 
 
 
 
 
 
